Jan A Staessen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3844708/publications.pdf

Version: 2024-02-01

750 papers 62,741 citations

109 h-index 229 g-index

765 all docs

765 docs citations

765 times ranked 44927 citing authors

#	Article	IF	CITATIONS
1	Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet, The, 1997, 350, 757-764.	6.3	2,841
2	Treatment of Hypertension in Patients 80 Years of Age or Older. New England Journal of Medicine, 2008, 358, 1887-1898.	13.9	2,714
3	Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature, 2011, 478, 103-109.	13.7	1,855
4	Predicting Cardiovascular Risk Using Conventional vs Ambulatory Blood Pressure in Older Patients With Systolic Hypertension. JAMA - Journal of the American Medical Association, 1999, 282, 539.	3.8	1,369
5	Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet, The, 1998, 352, 1347-1351.	6.3	1,336
6	New genetic loci link adipose and insulin biology to body fat distribution. Nature, 2015, 518, 187-196.	13.7	1,328
7	Prognostic Value of Aortic Pulse Wave Velocity as Index of Arterial Stiffness in the General Population. Circulation, 2006, 113, 664-670.	1.6	1,308
8	Genome-wide association study identifies 74 loci associated with educational attainment. Nature, 2016, 533, 539-542.	13.7	1,204
9	Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet, The, 2000, 355, 865-872.	6.3	1,136
10	European Society of Hypertension Position Paper on Ambulatory Blood Pressure Monitoring. Journal of Hypertension, 2013, 31, 1731-1768.	0.3	1,124
11	Superiority of Ambulatory Over Clinic Blood Pressure Measurement in Predicting Mortality. Hypertension, 2005, 46, 156-161.	1.3	1,098
12	Clinical applications of arterial stiffness; definitions and reference values. American Journal of Hypertension, 2002, 15, 426-444.	1.0	953
13	Effects of Calcium-Channel Blockade in Older Patients with Diabetes and Systolic Hypertension. New England Journal of Medicine, 1999, 340, 677-684.	13.9	911
14	Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet, The, 2001, 358, 1305-1315.	6.3	892
15	The Prevention of Dementia With Antihypertensive Treatment <subtitle>New Evidence From the Systolic Hypertension in Europe (Syst-Eur) Study</subtitle> . Archives of Internal Medicine, 2002, 162, 2046.	4.3	784
16	Prognostic accuracy of day versus night ambulatory blood pressure: a cohort study. Lancet, The, 2007, 370, 1219-1229.	6.3	766
17	European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring. Journal of Hypertension, 2014, 32, 1359-1366.	0.3	758
18	European Society of Hypertension guidelines for blood pressure monitoring at home: a summary report of the Second International Consensus Conference on Home Blood Pressure Monitoring. Journal of Hypertension, 2008, 26, 1505-1526.	0.3	707

#	Article	IF	CITATIONS
19	Circulating MicroRNA-208b and MicroRNA-499 Reflect Myocardial Damage in Cardiovascular Disease. Circulation: Cardiovascular Genetics, 2010, 3, 499-506.	5.1	683
20	Daytime and Nighttime Blood Pressure as Predictors of Death and Cause-Specific Cardiovascular Events in Hypertension. Hypertension, 2008, 51, 55-61.	1.3	644
21	Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Journal of Hypertension, 1998, 16, 1823-1829.	0.3	622
22	Environmental exposure to cadmium and risk of cancer: a prospective population-based study. Lancet Oncology, The, 2006, 7, 119-126.	5.1	517
23	Pulse Pressure Not Mean Pressure Determines Cardiovascular Risk in Older Hypertensive Patients. Archives of Internal Medicine, 2000, 160, 1085.	4.3	502
24	Fatal and Nonfatal Outcomes, Incidence of Hypertension, and Blood Pressure Changes in Relation to Urinary Sodium Excretion. JAMA - Journal of the American Medical Association, 2011, 305, 1777.	3.8	483
25	Predictive Role of the Nighttime Blood Pressure. Hypertension, 2011, 57, 3-10.	1.3	482
26	Cardiovascular prevention and blood pressure reduction. Journal of Hypertension, 2003, 21, 1055-1076.	0.3	427
27	Essential hypertension. Lancet, The, 2003, 361, 1629-1641.	6.3	415
28	Prognostic Value of Reading-to-Reading Blood Pressure Variability Over 24 Hours in 8938 Subjects From 11 Populations. Hypertension, 2010, 55, 1049-1057.	1.3	394
29	Gender and telomere length: Systematic review and meta-analysis. Experimental Gerontology, 2014, 51, 15-27.	1.2	394
30	Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. Lancet, The, 2009, 374, 525-533.	6.3	391
31	FTO genotype is associated with phenotypic variability of body mass index. Nature, 2012, 490, 267-272.	13.7	383
32	Environmental exposure to cadmium, forearm bone density, and risk of fractures: prospective population study. Lancet, The, 1999, 353, 1140-1144.	6.3	364
33	Cadmium exposure in the population: from health risks to strategies of prevention. BioMetals, 2010, 23, 769-782.	1.8	350
34	Prevalence, Persistence, and Clinical Significance of Masked Hypertension in Youth. Hypertension, 2005, 45, 493-498.	1.3	347
35	Ambulatory Arterial Stiffness Index as a Predictor of Cardiovascular Mortality in the Dublin Outcome Study. Hypertension, 2006, 47, 365-370.	1.3	346
36	Effect of Age on Brachial Artery Wall Properties Differs From the Aorta and Is Gender Dependent. Hypertension, 2000, 35, 637-642.	1.3	344

#	Article	IF	Citations
37	Telomere length and possible link to X chromosome. Lancet, The, 2004, 363, 507-510.	6.3	341
38	The deletion/insertion polymorphism of the angiotensin converting enzyme gene and cardiovascular-renal risk. Journal of Hypertension, 1997, 15, 1579-1592.	0.3	336
39	The Influence of Age and Sex on Genetic Associations with Adult Body Size and Shape: A Large-Scale Genome-Wide Interaction Study. PLoS Genetics, 2015, 11, e1005378.	1.5	331
40	Prognostic superiority of daytime ambulatory over conventional blood pressure in four populations: a meta-analysis of 7030 individuals. Journal of Hypertension, 2007, 25, 1554-1564.	0.3	328
41	Non-invasive assessment of local arterial pulse pressure: comparison of applanation tonometry and echo-tracking. Journal of Hypertension, 2001, 19, 1037-1044.	0.3	323
42	Prognostic value of isolated nocturnal hypertension on ambulatory measurement in 8711 individuals from 10 populations. Journal of Hypertension, 2010, 28, 2036-2045.	0.3	318
43	Angiotensin-Converting Enzyme Inhibitors and Calcium Channel Blockers for Coronary Heart Disease and Stroke Prevention. Hypertension, 2005, 46, 386-392.	1.3	317
44	Ambulatory Arterial Stiffness Index Derived From 24-Hour Ambulatory Blood Pressure Monitoring. Hypertension, 2006, 47, 359-364.	1.3	307
45	Systolic blood pressure variability as a risk factor for stroke and cardiovascular mortality in the elderly hypertensive population. Journal of Hypertension, 2003, 21, 2251-2257.	0.3	305
46	Prevalence of Left Ventricular Diastolic Dysfunction in a General Population. Circulation: Heart Failure, 2009, 2, 105-112.	1.6	291
47	Diagnostic Thresholds for Ambulatory Blood Pressure Monitoring Based on 10-Year Cardiovascular Risk. Circulation, 2007, 115, 2145-2152.	1.6	277
48	Response to Antihypertensive Therapy in Older Patients With Sustained and Nonsustained Systolic Hypertension. Circulation, 2000, 102, 1139-1144.	1.6	271
49	Nocturnal Blood Pressure Fall on Ambulatory Monitoring in a Large International Database. Hypertension, 1997, 29, 30-39.	1.3	269
50	Association of Office and Ambulatory Blood Pressure With Mortality and Cardiovascular Outcomes. JAMA - Journal of the American Medical Association, 2019, 322, 409.	3.8	265
51	Antihypertensive Treatment Based on Blood Pressure Measurement at Home or in the Physician's Office <subtitle>A Randomized Controlled Trial</subtitle> . JAMA - Journal of the American Medical Association, 2004, 291, 955.	3.8	262
52	Prognosis of White-Coat and Masked Hypertension. Hypertension, 2014, 63, 675-682.	1.3	262
53	Oral renin inhibitors. Lancet, The, 2006, 368, 1449-1456.	6.3	259
54	Prognostic Value of the Morning Blood Pressure Surge in 5645 Subjects From 8 Populations. Hypertension, 2010, 55, 1040-1048.	1.3	258

#	Article	IF	CITATIONS
55	Predictive Value of Clinic and Ambulatory Heart Rate for Mortality in Elderly Subjects With Systolic Hypertension. Archives of Internal Medicine, 2002, 162, 2313.	4.3	254
56	Systolic and Diastolic Blood Pressure Lowering as Determinants of Cardiovascular Outcome. Hypertension, 2005, 45, 907-913.	1.3	253
57	Carotid Intima-Media Thickness and Antihypertensive Treatment. Stroke, 2006, 37, 1933-1940.	1.0	253
58	Results of the pilot study for the Hypertension in the Very Elderly Trial. Journal of Hypertension, 2003, 21, 2409-2417.	0.3	243
59	Obesity is associated with increased arterial stiffness from adolescence until old age. Journal of Hypertension, 2005, 23, 1839-1846.	0.3	235
60	Blood Pressure Reduction and Cardiovascular Prevention: An Update Including the 2003-2004 Secondary Prevention Trials. Hypertension Research, 2005, 28, 385-407.	1.5	229
61	Impairment of Renal Function with Increasing Blood Lead Concentrations in the General Population. New England Journal of Medicine, 1992, 327, 151-156.	13.9	228
62	Metaâ€nnalysis of continuous outcomes combining individual patient data and aggregate data. Statistics in Medicine, 2008, 27, 1870-1893.	0.8	222
63	Polygenic prediction of educational attainment within and between families from genome-wide association analyses in 3 million individuals. Nature Genetics, 2022, 54, 437-449.	9.4	215
64	Mean and range of the ambulatory pressure in normotensive subjects from a meta-analysis of 23 studies. American Journal of Cardiology, 1991, 67, 723-727.	0.7	206
65	Effects of three candidate genes on prevalence and incidence of hypertension in a Caucasian population. Journal of Hypertension, 2001, 19, 1349-1358.	0.3	205
66	Diagnosis and Prediction of CKD Progression by Assessment of Urinary Peptides. Journal of the American Society of Nephrology: JASN, 2015, 26, 1999-2010.	3.0	205
67	Sexual maturation in relation to polychlorinated aromatic hydrocarbons: Sharpe and Skakkebaek's hypothesis revisited Environmental Health Perspectives, 2002, 110, 771-776.	2.8	204
68	Left ventricular strain and strain rate in a general population. European Heart Journal, 2008, 29, 2014-2023.	1.0	188
69	M235T angiotensinogen gene polymorphism and cardiovascular renal risk. Journal of Hypertension, 1999, 17, 9-17.	0.3	186
70	House dust as possible route of environmental exposure to cadmium and lead in the adult general population. Environmental Research, 2007, 103, 30-37.	3.7	185
71	White-Coat Hypertension. Hypertension, 2013, 62, 982-987.	1.3	185
72	Renal function, cytogenetic measurements, and sexual development in adolescents in relation to environmental pollutants: a feasibility study of biomarkers. Lancet, The, 2001, 357, 1660-1669.	6.3	183

#	Article	IF	CITATIONS
73	Bone Resorption and Environmental Exposure to Cadmium in Women: A Population Study. Environmental Health Perspectives, 2008, 116, 777-783.	2.8	180
74	Significance of White-Coat Hypertension in Older Persons With Isolated Systolic Hypertension. Hypertension, 2012, 59, 564-571.	1.3	177
75	Prognostic Significance of Renal Function in Elderly Patients with Isolated Systolic Hypertension: Results from the Syst-Eur Trial. Journal of the American Society of Nephrology: JASN, 2002, 13, 2213-2222.	3.0	172
76	Effects of immediate versus delayed antihypertensive therapy on outcome in the Systolic Hypertension in Europe Trial. Journal of Hypertension, 2004, 22, 847-857.	0.3	172
77	Task Force II: Blood pressure measurement and cardiovacular outcome. Blood Pressure Monitoring, 2001, 6, 355-370.	0.4	170
78	Genome-wide meta-analysis of 241,258 adults accounting for smoking behaviour identifies novel loci for obesity traits. Nature Communications, 2017, 8, 14977.	5.8	169
79	Association of genetic variation with systolic and diastolic blood pressure among African Americans: the Candidate Gene Association Resource study. Human Molecular Genetics, 2011, 20, 2273-2284.	1.4	168
80	Antihypertensive Treatment Based on Conventional or Ambulatory Blood Pressure Measurement. JAMA - Journal of the American Medical Association, 1997, 278, 1065.	3.8	164
81	Treatment of hypertension in patients 80 years and older: the lower the better? A meta-analysis of randomized controlled trials. Journal of Hypertension, 2010, 28, 1366-1372.	0.3	160
82	Blood Pressure Loci Identified with a Gene-Centric Array. American Journal of Human Genetics, 2011, 89, 688-700.	2.6	159
83	Cardiac involvement in Churgâ€Strauss syndrome. Arthritis and Rheumatism, 2010, 62, 627-634.	6.7	158
84	Association Between More Intensive vs Less Intensive Blood Pressure Lowering and Risk of Mortality in Chronic Kidney Disease Stages 3 to 5. JAMA Internal Medicine, 2017, 177, 1498.	2.6	158
85	Cardiovascular outcomes in the first trial of antihypertensive therapy guided by self-measured home blood pressure. Hypertension Research, 2012, 35, 1102-1110.	1.5	157
86	Blood pressure reduction for the secondary prevention of stroke: a Chinese trial and a systematic review of the literature. Hypertension Research, 2009, 32, 1032-1040.	1.5	148
87	Evaluation of Adherence Should Become an Integral Part of Assessment of Patients With Apparently Treatment-Resistant Hypertension. Hypertension, 2016, 68, 297-306.	1.3	147
88	Prognostic Significance of Serum Creatinine and Uric Acid in Older Chinese Patients With Isolated Systolic Hypertension. Hypertension, 2001, 37, 1069-1074.	1.3	145
89	Genomewide Association Study Using a High-Density Single Nucleotide Polymorphism Array and Case-Control Design Identifies a Novel Essential Hypertension Susceptibility Locus in the Promoter Region of Endothelial NO Synthase. Hypertension, 2012, 59, 248-255.	1.3	144
90	Genetic polymorphisms in the renin–angiotensin system: relevance for susceptibility to cardiovascular disease. European Journal of Pharmacology, 2000, 410, 289-302.	1.7	142

#	Article	IF	CITATIONS
91	Masked Hypertension in Diabetes Mellitus. Hypertension, 2013, 61, 964-971.	1.3	142
92	Setting Thresholds to Varying Blood Pressure Monitoring Intervals Differentially Affects Risk Estimates Associated With White-Coat and Masked Hypertension in the Population. Hypertension, 2014, 64, 935-942.	1.3	137
93	Blood Pressure, Cognitive Functions, and Prevention of Dementias in Older Patients With Hypertension. Archives of Internal Medicine, 2001, 161, 152.	4.3	136
94	Pulsatile blood pressure component as predictor of mortality in hypertension: a meta-analysis of clinical trial control groups. Journal of Hypertension, 2002, 20, 145-151.	0.3	136
95	Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis. Lancet, The, 2021, 398, 1053-1064.	6.3	133
96	Cadmium-Related Mortality and Long-Term Secular Trends in the Cadmium Body Burden of an Environmentally Exposed Population. Environmental Health Perspectives, 2008, 116, 1620-1628.	2.8	132
97	The International Database of Ambulatory blood pressure in relation to Cardiovascular Outcome (IDACO): protocol and research perspectives. Blood Pressure Monitoring, 2007, 12, 255-262.	0.4	130
98	Ambulatory arterial stiffness index predicts stroke in a general population. Journal of Hypertension, 2006, 24, 2247-2253.	0.3	129
99	The Cardiovascular Risk of White-CoatÂHypertension. Journal of the American College of Cardiology, 2016, 68, 2033-2043.	1.2	129
100	Ambulatory Arterial Stiffness Index and 24-Hour Ambulatory Pulse Pressure as Predictors of Mortality in Ohasama, Japan. Stroke, 2007, 38, 1161-1166.	1.0	128
101	On-Treatment Diastolic Blood Pressure and Prognosis in Systolic Hypertension. Archives of Internal Medicine, 2007, 167, 1884.	4.3	124
102	Subgroup and Per-Protocol Analysis of the Randomized European Trial on Isolated Systolic Hypertension in the Elderly. Archives of Internal Medicine, 1998, 158, 1681.	4.3	123
103	Is Isolated Nocturnal Hypertension a Novel Clinical Entity?. Hypertension, 2007, 50, 333-339.	1.3	123
104	Reference Values for Self-recorded Blood Pressure. Archives of Internal Medicine, 1998, 158, 481.	4.3	120
105	24-h ambulatory recording of aortic pulse wave velocity and central systolic augmentation: a feasibility study. Hypertension Research, 2012, 35, 980-987.	1.5	120
106	Home Blood Pressure Variability as Cardiovascular Risk Factor in the Population of Ohasama. Hypertension, 2013, 61, 61-69.	1.3	120
107	Beat-to-Beat, Reading-to-Reading, and Day-to-Day Blood Pressure Variability in Relation to Organ Damage in Untreated Chinese. Hypertension, 2014, 63, 790-796.	1.3	120
108	Adducin Polymorphism. Hypertension, 2005, 45, 331-340.	1.3	116

#	Article	IF	CITATIONS
109	Follow-up of renal function in treated and untreated older patients with isolated systolic hypertension. Journal of Hypertension, 2001, 19, 511-519.	0.3	113
110	Genome-wide association study of kidney function decline in individuals of European descent. Kidney International, 2015, 87, 1017-1029.	2.6	113
111	Ambulatory Blood Pressure Monitoring in 9357 Subjects From 11 Populations Highlights Missed Opportunities for Cardiovascular Prevention in Women. Hypertension, 2011, 57, 397-405.	1.3	111
112	Genetic variants linked to education predict longevity. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 13366-13371.	3.3	110
113	Prediction of Cardiac Structure and Function by Repeated Clinic and Ambulatory Blood Pressure. Hypertension, 1997, 29, 22-29.	1.3	110
114	Quality control of the blood pressure phenotype in the European Project on Genes in Hypertension. Blood Pressure Monitoring, 2002, 7, 215-224.	0.4	109
115	Self-measured versus ambulatory blood pressure in the diagnosis of hypertension. Journal of Hypertension, 2003, 21, 717-722.	0.3	109
116	Within-Subject Blood Pressure Levelâ€"Not Variabilityâ€"Predicts Fatal and Nonfatal Outcomes in a General Population. Hypertension, 2012, 60, 1138-1147.	1.3	108
117	Less Atherosclerosis and Lower Blood Pressure for a Meaningful Life Perspective With More Brain. Hypertension, 2007, 49, 389-400.	1.3	107
118	Blood pressure as a prognostic factor after acute stroke. Lancet Neurology, The, 2009, 8, 938-948.	4.9	105
119	Salt and cardiovascular disease: insufficient evidence to recommend low sodium intake. European Heart Journal, 2020, 41, 3363-3373.	1.0	103
120	Blood pressure and blood selenium: a cross-sectional and longitudinal population study. European Heart Journal, 2006, 28, 628-633.	1.0	102
121	Blood Pressure Lowering for Primary and Secondary Prevention of Stroke. Hypertension, 2006, 48, 187-195.	1.3	100
122	Outcome-Driven Thresholds for Home Blood Pressure Measurement. Hypertension, 2013, 61, 27-34.	1.3	100
123	Advantages and disadvantages of the meta-analysis approach. Journal of Hypertension, 1996, 14, S9-S13.	0.3	98
124	Reference Values and Factors Associated With Renal Resistive Index in a Family-Based Population Study. Hypertension, 2014, 63, 136-142.	1.3	97
125	The relationships between left ventricular mass and daytime and night-time blood pressures: a meta-analysis of comparative studies. Journal of Hypertension, 1995, 13, 823-829.	0.3	95
126	Prognostic Value of Left Ventricular Diastolic Dysfunction in a General Population. Journal of the American Heart Association, 2014, 3, e000789.	1.6	95

#	Article	IF	CITATIONS
127	Genetic loci associated with heart rate variability and their effects on cardiac disease risk. Nature Communications, 2017, 8, 15805.	5.8	95
128	Prognostic Value of Masked Uncontrolled Hypertension. Hypertension, 2018, 72, 862-869.	1.3	94
129	Ambulatory pulse pressure aspredictor of outcome in older patients with systolic hypertension. American Journal of Hypertension, 2002, 15, 835-843.	1.0	93
130	Immunologic biomarkers in relation to exposure markers of PCBs and dioxins in Flemish adolescents (Belgium) Environmental Health Perspectives, 2002, 110, 595-600.	2.8	91
131	Correlates of Peripheral Blood Mitochondrial DNA Content in a General Population. American Journal of Epidemiology, 2016, 183, kwv175.	1.6	91
132	Renal Denervation. Hypertension, 2012, 60, 596-606.	1.3	90
133	Individual participant data metaâ€analysis to examine interactions between treatment effect and participantâ€level covariates: Statistical recommendations for conduct and planning. Statistics in Medicine, 2020, 39, 2115-2137.	0.8	90
134	Causal Effect of Plasminogen Activator Inhibitor Type 1 on Coronary Heart Disease. Journal of the American Heart Association, 2017, 6, .	1.6	89
135	Evidence that new antihypertensives are superior to older drugs. Lancet, The, 2005, 366, 869-871.	6. 3	88
136	Prognostic Value of Ambulatory Heart Rate Revisited in 6928 Subjects From 6 Populations. Hypertension, 2008, 52, 229-235.	1.3	87
137	A Consensus View on the Technique of Ambulatory Blood Pressure Monitoring. Hypertension, 1995, 26, 912-918.	1.3	86
138	Peroxisome Proliferator-Activated Receptor-Â2 Polymorphism Pro12Ala Is Associated With Nephropathy in Type 2 Diabetes: The Berlin Diabetes Mellitus (BeDiaM) Study. Diabetes, 2002, 51, 2653-2657.	0.3	85
139	Inactive Matrix Gla-Protein Is Associated With Arterial Stiffness in an Adult Population–Based Study. Hypertension, 2015, 66, 85-92.	1.3	85
140	Efficacy of Different Drug Classes Used to Initiate Antihypertensive Treatment in Black Subjects. Archives of Internal Medicine, 2001, 161, 965.	4.3	84
141	Carotid and Femoral Artery Stiffness in Relation to Three Candidate Genes in a White Population. Hypertension, 2001, 38, 1190-1197.	1.3	84
142	Ambulatory Hypertension Subtypes and 24-Hour Systolic and Diastolic Blood Pressure as Distinct Outcome Predictors in 8341 Untreated People Recruited From 12 Populations. Circulation, 2014, 130, 466-474.	1.6	84
143	Inactive Matrix Gla Protein Is Causally Related to Adverse Health Outcomes. Hypertension, 2015, 65, 463-470.	1.3	84
144	Metaâ€analysis of randomised trials with a continuous outcome according to baseline imbalance and availability of individual participant data. Statistics in Medicine, 2013, 32, 2747-2766.	0.8	83

#	Article	IF	CITATIONS
145	Influence of demographic, anthropometric and lifestyle characteristics on heart rate and its variability in the population. Journal of Hypertension, 1999, 17, 1589-1599.	0.3	82
146	Blood pressure variability in relation to outcome in the International Database of Ambulatory blood pressure in relation to Cardiovascular Outcome. Hypertension Research, 2010, 33, 757-766.	1.5	80
147	Urinary proteome analysis in hypertensive patients with left ventricular diastolic dysfunction. European Heart Journal, 2012, 33, 2342-2350.	1.0	79
148	Prognostic Value of Invasive Hemodynamic Measurements at Rest and During Exercise in Hypertensive Men. Hypertension, 1996, 28, 31-36.	1.3	79
149	Age-Specific Differences Between Conventional and Ambulatory Daytime Blood Pressure Values. Hypertension, 2014, 64, 1073-1079.	1.3	78
150	Investigation of antihypertensive class, dementia, and cognitive decline. Neurology, 2020, 94, e267-e281.	1.5	78
151	The relationship between blood pressure and sodium and potassium excretion during the day and at night. Journal of Hypertension, 1993, 11, 443-447.	0.3	77
152	Renal Nerve Stimulation–Induced Blood Pressure Changes Predict Ambulatory Blood Pressure Response After Renal Denervation. Hypertension, 2016, 68, 707-714.	1.3	77
153	Prediction of Chronic Kidney Disease Stage 3 by CKD273, a Urinary Proteomic Biomarker. Kidney International Reports, 2017, 2, 1066-1075.	0.4	77
154	The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart †OMics†in AGEing (HOMAGE) randomized clinical trial. European Heart Journal, 2021, 42, 684-696.	1.0	77
155	Task Force IV: Clinical use of ambulatory blood pressure monitoring. Blood Pressure Monitoring, 1999, 4, 319-331.	0.4	76
156	Association of total cancer and lung cancer with environmental exposure to cadmium: the meta-analytical evidence. Cancer Causes and Control, 2015, 26, 1281-1288.	0.8	75
157	Prognosis in Relation to Blood Pressure Variability. Hypertension, 2015, 65, 1170-1179.	1.3	74
158	Correlates of cognitive status of old patients with isolated systolic hypertension. Journal of Hypertension, 1998, 16, 963-969.	0.3	73
159	Adducin- and Ouabain-Related Gene Variants Predict the Antihypertensive Activity of Rostafuroxin, Part 2: Clinical Studies. Science Translational Medicine, 2010, 2, 59ra87.	5.8	73
160	A urinary proteome-based classifier for the early detection of decline in glomerular filtration. Nephrology Dialysis Transplantation, 2017, 32, gfw239.	0.4	73
161	Additive Prognostic Value of Left Ventricular Systolic Dysfunction in a Population-Based Cohort. Circulation: Cardiovascular Imaging, 2016, 9, .	1.3	73
162	Progress in Cardiovascular Diseases. Progress in Cardiovascular Diseases, 2006, 49, 1-10.	1.6	72

#	Article	IF	Citations
163	Risk Stratification by Self-Measured Home Blood Pressure across Categories of Conventional Blood Pressure: A Participant-Level Meta-Analysis. PLoS Medicine, 2014, 11, e1001591.	3.9	72
164	An epidemiological study of blood pressure and metabolic phenotypes in relation to the $G\hat{l}^2$ 3 C825T polymorphism. Journal of Hypertension, 2003, 21, 729-737.	0.3	71
165	Ambulatory arterial stiffness index: rationale and methodology. Blood Pressure Monitoring, 2006, 11, 103-105.	0.4	69
166	Public health implications of environmental exposure to cadmium and lead: an overview of epidemiological studies in Belgium. European Journal of Cardiovascular Prevention and Rehabilitation, 1996, 3, 26-41.	1.5	68
167	Prevalence of left ventricular diastolic dysfunction in European populations based on cross-validated diagnostic thresholds. Cardiovascular Ultrasound, 2012, 10, 10.	0.5	68
168	CXCL10 Is a Circulating Inflammatory Marker in Patients with Advanced Heart Failure: a Pilot Study. Journal of Cardiovascular Translational Research, 2016, 9, 302-314.	1.1	68
169	Blood Pressure Measurement and Treatment Decisions. Circulation Research, 2019, 124, 990-1008.	2.0	68
170	Left Ventricular Mass in Relation to Genetic Variation in Angiotensin II Receptors, Renin System Genes, and Sodium Excretion. Circulation, 2004, 110, 2644-2650.	1.6	67
171	Placebo-Controlled Trials of Blood Pressure–Lowering Therapies for Primary Prevention of Dementia. Hypertension, 2011, 57, e6-7.	1.3	67
172	Does White Coat Hypertension Require Treatment Over Age 80?. Hypertension, 2013, 61, 89-94.	1.3	67
173	Impact of Environmental Cadmium Pollution on Cadmium Exposure and Body Burden. Archives of Environmental Health, 1992, 47, 347-353.	0.4	66
174	Genetic variability in the renin-angiotensin system: prevalence of alleles and genotypes. European Journal of Cardiovascular Prevention and Rehabilitation, 1997, 4, 401-422.	1.5	66
175	Calcium Channel Blockade and Cardiovascular Prognosis in the European Trial on Isolated Systolic Hypertension. Hypertension, 1998, 32, 410-416.	1.3	66
176	Determinants of white-coat syndrome assessed by ambulatory blood pressure or self-measured home blood pressure. Blood Pressure Monitoring, 2003, 8, 37-40.	0.4	66
177	Are published characteristics of the ambulatory blood pressure generalizable to rural Chinese? The JingNing population study. Blood Pressure Monitoring, 2005, 10, 125-134.	0.4	66
178	Low-Density Lipoprotein Cholesterol and Mortality in Older People. Journal of the American Geriatrics Society, 2005, 53, 2159-2164.	1.3	66
179	Blood pressure reduction and renin-angiotensin system inhibition for prevention of congestive heart failure: a meta-analysis. European Heart Journal, 2008, 30, 679-688.	1.0	66
180	Individual patient data meta-analysis of survival data using Poisson regression models. BMC Medical Research Methodology, 2012, 12, 34.	1.4	66

#	Article	IF	CITATIONS
181	The International Database of Self-Recorded Blood Pressures in normotensive and untreated hypertensive subjects. Blood Pressure Monitoring, 1999, 4, 77-86.	0.4	66
182	Calcium channel blockade to prevent stroke in hypertension: a meta-analysis of 13 studies with 103,793 subjects. American Journal of Hypertension, 2004, 17, 817-822.	1.0	65
183	Reference Values in White Europeans for the Arterial Pulse Wave Recorded by Means of the SphygmoCor Device. Hypertension Research, 2006, 29, 475-483.	1.5	65
184	Meta-analysis of randomized controlled trials of renal denervation in treatment-resistant hypertension. Blood Pressure, 2015, 24, 263-274.	0.7	65
185	Masked Hypertension. Hypertension, 2015, 65, 16-20.	1.3	65
186	Outcome-Driven Thresholds for Increased Home Blood Pressure Variability. Hypertension, 2017, 69, 599-607.	1.3	65
187	Ambulatory blood pressure in normotensive and hypertensive subjects. Journal of Hypertension, 1994, 12, S13???S22.	0.3	64
188	Relationships between changes in left ventricular mass and in clinic and ambulatory blood pressure in response to antihypertensive therapy. Journal of Hypertension, 1997, 15, 1493-1502.	0.3	64
189	Association between hypertension and variation in the \hat{l}_{\pm} - and \hat{l}_{\pm} -adducin genes in a white population. Kidney International, 2002, 62, 2152-2159.	2.6	64
190	When can the practicing physician suspect white coat hypertension? Statement from the Working Group on Blood Pressure Monitoring of the European Society of Hypertension. American Journal of Hypertension, 2003, 16, 87-91.	1.0	64
191	Salt, endogenous ouabain and blood pressure interactions in the general population. Journal of Hypertension, 2003, 21, 1475-1481.	0.3	64
192	Prognostic Significance of Electrocardiographic Voltages and Their Serial Changes in Elderly With Systolic Hypertension. Hypertension, 2004, 44, 459-464.	1.3	64
193	Masked hypertension: understanding its complexity. European Heart Journal, 2017, 38, ehw502.	1.0	64
194	Treatment of isolated systolic hypertension in the elderly: further evidence from the Systolic Hypertension in Europe (Syst-Eur) trial. American Journal of Cardiology, 1998, 82, 20-22.	0.7	63
195	Cardiovascular Risk In White-coat and Sustained Hypertensive Patients. Blood Pressure, 2002, 11, 352-356.	0.7	63
196	Self-Measurement of Blood Pressure at Home in the Management of Hypertension. Clinical Medicine and Research, 2005, 3, 19-26.	0.4	63
197	Reference Values for SphygmoCor Measurements in South Africans of African Ancestry. American Journal of Hypertension, 2006, 19, 40-46.	1.0	63
198	Prognostic significance of ambulatory blood pressure in hypertensive patients with history of cardiovascular disease. Blood Pressure Monitoring, 2008, 13, 325-332.	0.4	63

#	Article	IF	CITATIONS
199	Branched-Chain Amino Acids as Critical Switches in Health and Disease. Hypertension, 2018, 72, 1012-1022.	1.3	63
200	Proteomic Bioprofiles and Mechanistic Pathways of Progression to Heart Failure. Circulation: Heart Failure, 2019, 12, e005897.	1.6	63
201	Low-Level Environmental Exposure to Lead Unmasked as Silent Killer. Circulation, 2006, 114, 1347-1349.	1.6	62
202	Blood Flow Pattern in the Middle Cerebral Artery in Relation to Indices of Arterial Stiffness in the Systemic Circulation. American Journal of Hypertension, 2012, 25, 319-324.	1.0	62
203	Host and environmental determinants of heart rate and heart rate variability in four European populations. Journal of Hypertension, 2003, 21, 525-535.	0.3	61
204	Eligibility for Renal Denervation. Hypertension, 2014, 63, 1319-1325.	1.3	61
205	Impact and pitfalls of scaling of left ventricular and atrial structure in population-based studies. Journal of Hypertension, 2016, 34, 1186-1194.	0.3	60
206	The pulse pressure-to-stroke index ratio predicts cardiovascular events and death in uncomplicated hypertension. Journal of the American College of Cardiology, 2001, 38, 227-231.	1.2	59
207	Angiotensin-Converting Enzyme I/D and α-Adducin Gly460Trp Polymorphisms. Hypertension, 2007, 49, 1291-1297.	1.3	59
208	Carotid and femoral intima–media thickness in relation to three candidate genes in a Caucasian population. Journal of Hypertension, 2002, 20, 1551-1561.	0.3	58
209	Hypertension Prevalence and Stroke Mortality Across Populations. JAMA - Journal of the American Medical Association, 2003, 289, 2420.	3.8	58
210	Independent Relations of Left Ventricular Structure With the 24-Hour Urinary Excretion of Sodium and Aldosterone. Hypertension, 2009, 54, 489-495.	1.3	58
211	Blood Pressure in Relation to Environmental Lead Exposure in the National Health and Nutrition Examination Survey 2003 to 2010. Hypertension, 2015, 65, 62-69.	1.3	58
212	Short-term and long-term repeatability of the morning blood pressure in older patients with isolated systolic hypertension. Journal of Hypertension, 2008, 26, 1328-1335.	0.3	57
213	The urinary proteome as correlate and predictor of renal function in a population study. Nephrology Dialysis Transplantation, 2014, 29, 2260-2268.	0.4	57
214	Terminal digit preference and single-number preference in the Syst-Eur trial: influence of quality control. Blood Pressure Monitoring, 2002, 7, 169-177.	0.4	56
215	Endothelial function and outdoor temperature. European Journal of Epidemiology, 2005, 20, 407-410.	2.5	56
216	Epidemiology of Masked and White-Coat Hypertension: The Family-Based SKIPOGH Study. PLoS ONE, 2014, 9, e92522.	1.1	56

#	Article	IF	CITATIONS
217	Prevalence, Treatment, and Control Rates of Conventional and Ambulatory Hypertension Across 10 Populations in 3 Continents. Hypertension, 2017, 70, 50-58.	1.3	56
218	Blood Pressure and Renal Sodium Handling in Relation to Genetic Variation in the <i>DRD1</i> Promoter and <i>GRK4</i> I>. Hypertension, 2008, 51, 1643-1650.	1.3	54
219	Higher circulating levels of IGF-1 are associated with longer leukocyte telomere length in healthy subjects. Mechanisms of Ageing and Development, 2009, 130, 771-776.	2.2	54
220	Ethnic differences in proximal and distal tubular sodium reabsorption are heritable in black and white populations. Journal of Hypertension, 2009, 27, 606-612.	0.3	54
221	Hypertension caused by low-level lead exposure: myth or fact?. European Journal of Cardiovascular Prevention and Rehabilitation, 1994, 1, 87-97.	1.5	53
222	Lead Exposure and Conventional and Ambulatory Blood Pressure. JAMA - Journal of the American Medical Association, 1996, 275, 1563.	3.8	53
223	Uncoupling protein 1 and 3 polymorphisms are associated with waist-to-hip ratio. Journal of Molecular Medicine, 2003, 81, 327-332.	1.7	53
224	Telomere length and its associations with oxidized-LDL carotid artery distensibility and smoking. Frontiers in Bioscience - Elite, 2010, E2, 1164-1168.	0.9	53
225	Association Between Left Ventricular Mass and Telomere Length in a Population Study. American Journal of Epidemiology, 2010, 172, 440-450.	1.6	53
226	Blood Pressure Measurement Anno 2016. American Journal of Hypertension, 2017, 30, hpw148.	1.0	52
227	Renal Versus Extrarenal Activation of Vitamin D in Relation to Atherosclerosis, Arterial Stiffening, and Hypertension. American Journal of Hypertension, 2007, 20, 1007-1015.	1.0	51
228	Ambulatory Blood Pressure Monitoring to Diagnose and Manage Hypertension. Hypertension, 2021, 77, 254-264.	1.3	51
229	Renal function in relation to three candidate genes. American Journal of Kidney Diseases, 2001, 38, 1158-1168.	2.1	50
230	Progression to hypertension in the non-hypertensive participants in the Flemish Study on Environment, Genes and Health Outcomes. Journal of Hypertension, 2006, 24, 1719-1727.	0.3	50
231	Blood-pressure lowering for the secondary prevention of stroke. Lancet, The, 2001, 358, 1026-1027.	6.3	49
232	\hat{l}^2 -Adducin polymorphisms, blood pressure, and sodium excretion in three European populations. American Journal of Hypertension, 2003, 16, 840-846.	1.0	49
233	Sympathetic activity, assessed by power spectral analysis of heart rate variability, in white-coat, masked and sustained hypertension versus true normotension. Journal of Hypertension, 2007, 25, 2280-2285.	0.3	49
234	How Many Measurements Are Needed to Estimate Blood Pressure Variability Without Loss of Prognostic Information?. American Journal of Hypertension, 2014, 27, 46-55.	1.0	49

#	Article	IF	CITATIONS
235	Risk Stratification by Ambulatory Blood Pressure Monitoring Across JNC Classes of Conventional Blood Pressure. American Journal of Hypertension, 2014, 27, 956-965.	1.0	49
236	Ambulatory Blood Pressure and Blood Pressure Measured at Home. Journal of Cardiovascular Pharmacology, 1994, 23, S5-S11.	0.8	48
237	Cardiovascular Risk in Relation to α-Adducin Gly460Trp Polymorphism and Systolic Pressure. Hypertension, 2005, 46, 527-532.	1.3	48
238	Thirty years of research on diagnostic and therapeutic thresholds for the self-measured blood pressure at home. Blood Pressure Monitoring, 2008, 13, 352-365.	0.4	48
239	Target Sequencing, Cell Experiments, and a Population Study Establish Endothelial Nitric Oxide Synthase (<i>eNOS</i>) Gene as Hypertension Susceptibility Gene. Hypertension, 2013, 62, 844-852.	1.3	48
240	Sexual Dimorphism in the Transition From Masked to Sustained Hypertension in Healthy Youths. Hypertension, 2013, 62, 410-414.	1.3	48
241	Renal function estimation and Cockcroft–Gault formulas for predicting cardiovascular mortality in population-based, cardiovascular risk, heart failure and post-myocardial infarction cohorts: The Heart  OMics' in AGEing (HOMAGE) and the high-risk myocardial infarction database initiatives. BMC Medicine. 2016. 14. 181.	2.3	48
242	Comparison of Three Measures of the Ankle-Brachial Blood Pressure Index in a General Population. Hypertension Research, 2007, 30, 555-561.	1.5	47
243	Effects of Intensive Blood Pressure Treatment on Orthostatic Hypotension. Annals of Internal Medicine, 2021, 174, 58-68.	2.0	47
244	Data Sharing Under the General Data Protection Regulation. Hypertension, 2021, 77, 1029-1035.	1.3	47
245	Life Style as a Determinant of Blood Pressure in the General Population. American Journal of Hypertension, 1994, 7, 685-694.	1.0	46
246	Update on the Systolic Hypertension in Europe (Syst-Eur) Trial. Hypertension, 1999, 33, 1476-1477.	1.3	46
247	Night-time blood pressure. Journal of Hypertension, 2002, 20, 2131-2133.	0.3	46
248	Strategies for Classifying Patients Based on Office, Home, and Ambulatory Blood Pressure Measurement. Hypertension, 2015, 65, 1258-1265.	1.3	46
249	Catch–up growth in the first two years of life in Extremely Low Birth Weight (ELBW) infants is associated with lower body fat in young adolescence. PLoS ONE, 2017, 12, e0173349.	1.1	46
250	Proteomic and Mechanistic Analysis of Spironolactone in Patients at Risk for HF. JACC: Heart Failure, 2021, 9, 268-277.	1.9	46
251	Genetic Variation in CYP11B2 and AT1R Influences Heart Rate Variability Conditional on Sodium Excretion. Hypertension, 2004, 44, 156-162.	1.3	45
252	Impact of Hypertension on Ventricular-Arterial Coupling and Regional Myocardial Work at Rest and during Isometric Exercise. Journal of the American Society of Echocardiography, 2012, 25, 882-890.	1,2	45

#	Article	IF	CITATIONS
253	Predictive power of home blood pressure and clinic blood pressure in hypertensive patients with impaired glucose metabolism and diabetes. Journal of Hypertension, 2013, 31, 1593-1602.	0.3	45
254	Implications of Recently Published Trials of Blood Pressure–Lowering Drugs in Hypertensive or High-Risk Patients. Hypertension, 2010, 55, 819-831.	1.3	44
255	Left ventricular diastolic function in relation to the urinary proteome: A proof-of-concept study in a general population. International Journal of Cardiology, 2014, 176, 158-165.	0.8	44
256	Longitudinal Changes in Left Ventricular Diastolic Function in a General Population. Circulation: Cardiovascular Imaging, 2015, 8, .	1.3	44
257	Doppler Indexes of Left Ventricular Systolic and Diastolic Flow and Central Pulse Pressure in Relation to Renal Resistive Index. American Journal of Hypertension, 2015, 28, 535-545.	1.0	44
258	Vitamin K Dependent Protection of Renal Function in Multi-ethnic Population Studies. EBioMedicine, 2016, 4, 162-169.	2.7	44
259	Association between carotid diameter and the advanced glycation endproduct Nepsilon-Carboxymethyllysine (CML). Cardiovascular Diabetology, 2009, 8, 45.	2.7	43
260	Time to re-appraise the role of alpha-1 adrenoceptor antagonists in the management of hypertension?. Journal of Hypertension, 2010, 28, 1796-1803.	0.3	43
261	The Metabolic Syndrome and Carotid Intima-Media Thickness in Relation to the Parathyroid Hormone to 25-OH-D3 Ratio in a General Population. American Journal of Hypertension, 2011, 24, 102-109.	1.0	43
262	Effects of spironolactone on serum markers of fibrosis in people at high risk of developing heart failure: rationale, design and baseline characteristics of a proofâ€ofâ€concept, randomised, precisionâ€medicine, prevention trial. The Heart OMics in AGing (HOMAGE) trial. European Journal of Heart Failure, 2020, 22, 1711-1723.	2.9	43
263	Host and environmental determinants of polychlorinated aromatic hydrocarbons in serum of adolescents Environmental Health Perspectives, 2002, 110, 583-589.	2.8	42
264	Left Ventricular Structure and Function in Relation to Environmental Exposure to Lead and Cadmium. Journal of the American Heart Association, $2017, 6, \ldots$	1.6	42
265	Randomised Double-Blind Comparison of Placebo and Active Drugs for Effects on Risks Associated with Blood Pressure Variability in the Systolic Hypertension in Europe Trial. PLoS ONE, 2014, 9, e103169.	1.1	42
266	Urinary Proteomics Pilot Study for Biomarker Discovery and Diagnosis in Heart Failure with Reduced Ejection Fraction. PLoS ONE, 2016, 11, e0157167.	1.1	42
267	Blood pressure in relation to three candidate genes in a Chinese population. Journal of Hypertension, 2004, 22, 937-944.	0.3	41
268	Cardiovascular Outcome in Relation to Progression to Hypertension in the Copenhagen MONICA Cohort. American Journal of Hypertension, 2007, 20, 483-491.	1.0	41
269	Persistence of Mortality Reduction After the End of Randomized Therapy in Clinical Trials of Blood Pressure–Lowering Medications. Hypertension, 2010, 56, 1060-1068.	1.3	41
270	Association of Target Organ Damage With 24-Hour Systolic and Diastolic Blood Pressure Levels and Hypertension Subtypes in Untreated Chinese. Hypertension, 2014, 63, 222-228.	1.3	41

#	Article	IF	Citations
271	Risk for Incident Heart Failure: A Subjectâ€Level Metaâ€Analysis From the Heart "OMics―in AGEing (HOMAGE) Study. Journal of the American Heart Association, 2017, 6, .	1.6	41
272	Outcome beyond blood pressure control?. European Heart Journal, 2003, 24, 504-514.	1.0	40
273	Steroid Biosynthesis and Renal Excretion in Human Essential Hypertension: Association With Blood Pressure and Endogenous Ouabain. American Journal of Hypertension, 2009, 22, 357-363.	1.0	40
274	Outcome-Driven Thresholds for Ambulatory Pulse Pressure in 9938 Participants Recruited From 11 Populations. Hypertension, 2014, 63, 229-237.	1.3	40
275	Left Ventricular Dysfunction and CXCR3 Ligands in Hypertension: From Animal Experiments to a Population-Based Pilot Study. PLoS ONE, 2015, 10, e0141394.	1.1	40
276	Optimal Number of Days for Home Blood Pressure Measurement. American Journal of Hypertension, 2015, 28, 595-603.	1.0	40
277	Persistent Increase in Blood Pressure After Renal Nerve Stimulation in Accessory Renal Arteries After Sympathetic Renal Denervation. Hypertension, 2016, 67, 1211-1217.	1.3	40
278	Systolic and diastolic left ventricular dysfunction: from risk factors to overt heart failure. Expert Review of Cardiovascular Therapy, 2010, 8, 251-258.	0.6	39
279	Blood Pressure Load Does Not Add to Ambulatory Blood Pressure Level for Cardiovascular Risk Stratification. Hypertension, 2014, 63, 925-933.	1.3	39
280	Day–night blood pressure variations: mechanisms, reproducibility and clinical relevance. Journal of Hypertension, 2007, 25, 2377-2380.	0.3	38
281	Determinants of the Ambulatory Arterial Stiffness Index in 7604 Subjects From 6 Populations. Hypertension, 2008, 52, 1038-1044.	1.3	37
282	Main results of the Ouabain and Adducin for Specific Intervention on Sodium in Hypertension Trial (OASIS-HT): a randomized placebo-controlled phase-2 dose-finding study of rostafuroxin. Trials, 2011, 12, 13.	0.7	37
283	Sodium and Potassium and the Pathogenesis of Hypertension. Current Hypertension Reports, 2013, 15, 122-130.	1.5	37
284	Double Product Reflects the Predictive Power of Systolic Pressure in the General Population: Evidence from 9,937 Participants. American Journal of Hypertension, 2013, 26, 665-672.	1.0	37
285	Hyperresponders vs. nonresponder patients after renal denervation. Journal of Hypertension, 2014, 32, 2422-2427.	0.3	37
286	Diurnal Blood Pressure Rhythmicity in Relation to Environmental and Genetic Cues in Untreated Referred Patients. Hypertension, 2017, 69, 128-135.	1.3	37
287	Urinary peptides in heart failure: a link to molecular pathophysiology. European Journal of Heart Failure, 2021, 23, 1875-1887.	2.9	37
288	Anthropometric and lifestyle factors associated with white-coat, masked and sustained hypertension in a Chinese population. Journal of Hypertension, 2007, 25, 2398-2405.	0.3	36

#	Article	IF	Citations
289	Validation of automated oscillometric versus manual measurement of the ankle–brachial index. Hypertension Research, 2009, 32, 884-888.	1.5	36
290	Association of central and peripheral pulse pressure with intermediate cardiovascular phenotypes. Journal of Hypertension, 2012, 30, 67-74.	0.3	36
291	Genome-wide response to antihypertensive medication using home blood pressure measurements: a pilot study nested within the HOMED-BP study. Pharmacogenomics, 2013, 14, 1709-1721.	0.6	36
292	Defining Thresholds for Home Blood Pressure Monitoring in Octogenarians. Hypertension, 2015, 66, 865-873.	1.3	36
293	Arterial Characteristics in Normotensive Offspring of Parents With or Without a History of Hypertension. American Journal of Hypertension, 2006, 19, 264-269.	1.0	35
294	Dual inhibition of the renin system by aliskiren and valsartan. Lancet, The, 2007, 370, 195-196.	6.3	35
295	Longitudinal Changes in LV Structure and Diastolic Function in Relation to Arterial Properties in GeneralÂPopulation. JACC: Cardiovascular Imaging, 2017, 10, 1307-1316.	2.3	35
296	Left ventricular function in relation to chronic residential air pollution in a general population. European Journal of Preventive Cardiology, 2017, 24, 1416-1428.	0.8	35
297	Relation of Insulin Resistance to Longitudinal Changes in Left Ventricular Structure and Function in a General Population. Journal of the American Heart Association, 2018, 7, .	1.6	35
298	Fourier Analysis of Blood Pressure Profiles. American Journal of Hypertension, 1993, 6, 184S-187S.	1.0	34
299	Association of peripheral and central arterial wave reflections with the CYP11B2 ???344C allele and sodium excretion. Journal of Hypertension, 2004, 22, 2311-2319.	0.3	34
300	Diagnostic Thresholds for Ambulatory Blood Pressure Moving Lower: A Review Based on a Meta-Analysis—Clinical Implications. Journal of Clinical Hypertension, 2008, 10, 377-381.	1.0	34
301	The International Database of HOme blood pressure in relation to Cardiovascular Outcome (IDHOCO): moving from baseline characteristics to research perspectives. Hypertension Research, 2012, 35, 1072-1079.	1.5	34
302	Transfer of cadmium from a sandy acidic soil to man: A population study. Environmental Research, 1992, 58, 25-34.	3.7	33
303	If only cardiologists did properly measure blood pressure. Journal of the American College of Cardiology, 2002, 40, 2201-2203.	1.2	33
304	Breastfeeding leads to lower blood pressure in 7-year-old Japanese children: Tohoku Study of Child Development. Hypertension Research, 2013, 36, 117-122.	1.5	33
305	Urinary Proteome and Systolic Blood Pressure as Predictors of 5-Year Cardiovascular and Cardiac Outcomes in a General Population. Hypertension, 2015, 66, 52-60.	1.3	33
306	Desphospho-uncarboxylated matrix Gla protein is a novel circulating biomarker predicting deterioration of renal function in the general population. Nephrology Dialysis Transplantation, 2018, 33, 1122-1128.	0.4	33

#	Article	IF	CITATIONS
307	Vitamin K–Dependent Matrix Gla Protein as Multifaceted Protector of Vascular and Tissue Integrity. Hypertension, 2019, 73, 1160-1169.	1.3	33
308	Cardiovascular End Points and Mortality Are Not Closer Associated With Central Than Peripheral Pulsatile Blood Pressure Components. Hypertension, 2020, 76, 350-358.	1.3	33
309	What is "hypertension�. Lancet, The, 1999, 353, 1541-1543.	6.3	32
310	Relationships of heart rate and heart rate variability with conventional and ambulatory blood pressure in the population. Journal of Hypertension, 2001, 19, 389-397.	0.3	32
311	Renal Denervation for Treatment of Hypertension: a Second Start and New Challenges. Current Hypertension Reports, 2016, 18, 6.	1.5	32
312	Ambulatory blood pressure of adults in Novosibirsk, Russia: interim report on a population study. Blood Pressure Monitoring, 2000, 5, 291-296.	0.4	31
313	Calcium-channel blockade and cardiovascular prognosis: recent evidence from clinical outcome trials. American Journal of Hypertension, 2002, 15, S85-S93.	1.0	31
314	Epistatic interaction between \hat{l}_{\pm} - and \hat{l}^3 -adducin influences peripheral and central pulse pressures in white Europeans. Journal of Hypertension, 2005, 23, 961-969.	0.3	31
315	Ambulatory arterial stiffness index: determinants and outcome. Blood Pressure Monitoring, 2006, 11, 107-110.	0.4	31
316	In-Hospital Mortality Among Black Patients Admitted for Hypertension-Related Disorders in Mbuji Mayi, Congo. American Journal of Hypertension, 2009, 22, 643-648.	1.0	31
317	Of fads, fashion, surrogate endpoints and dual RAS blockade. European Heart Journal, 2010, 31, 2205-2208.	1.0	31
318	Hypertension Control in Community Health Centers Across China: Analysis of Antihypertensive Drug Treatment Patterns. American Journal of Hypertension, 2014, 27, 252-259.	1.0	31
319	Tight Versus Standard Blood Pressure Control in Patients With Hypertension With and Without Cardiovascular Disease. Hypertension, 2014, 63, 475-482.	1.3	31
320	Biomarkers of cardiomyocyte injury and stress identify left atrial and left ventricular remodelling and dysfunction: A population-based study. International Journal of Cardiology, 2015, 185, 177-185.	0.8	31
321	Sham or no sham control: that is the question in trials of renal denervation for resistant hypertension. A systematic meta-analysis. Blood Pressure, 2017, 26, 195-203.	0.7	31
322	Opposing Age-Related Trends in Absolute and Relative Risk of Adverse Health Outcomes Associated With Out-of-Office Blood Pressure. Hypertension, 2019, 74, 1333-1342.	1.3	31
323	Xanthine oxidase gene variants and their association with blood pressure and incident hypertension. Journal of Hypertension, 2016, 34, 2147-2154.	0.3	30
324	Novel Urinary Peptidomic Classifier Predicts Incident Heart Failure. Journal of the American Heart Association, 2017, 6, .	1.6	30

#	Article	IF	CITATIONS
325	Prediction of acute coronary syndromes by urinary proteome analysis. PLoS ONE, 2017, 12, e0172036.	1.1	30
326	Are low dehydroepiandrosterone sulphate levels predictive for cardiovascular diseases?. Acta Cardiologica, 2003, 58, 403-410.	0.3	30
327	Antihypertensive treatment based on home or office blood pressure???the THOP trial. Blood Pressure Monitoring, 2004, 9, 311-314.	0.4	29
328	Heritability and intrafamilial aggregation of arterial characteristics. Journal of Hypertension, 2008, 26, 721-728.	0.3	29
329	Age dependency of peripheral and central systolic blood pressures: cross-sectional and longitudinal observations in a Chinese population. Hypertension Research, 2012, 35, 115-122.	1.5	29
330	Renal function in relation to sodium intake: aÂquantitative review of the literature. Kidney International, 2017, 92, 67-78.	2.6	29
331	Cardiovascular Risk Associated With White-Coat Hypertension. Hypertension, 2017, 70, 676-682.	1.3	29
332	Evidence-based proposal for the number of ambulatory readings required for assessing blood pressure level in research settings: an analysis of the IDACO database. Blood Pressure, 2018, 27, 341-350.	0.7	29
333	Incidence of Cardiovascular Events in Patients Treated With Immune Checkpoint Inhibitors. Journal of Clinical Oncology, 2022, 40, 3430-3438.	0.8	29
334	Potential adverse effects of blood pressure loweringâ€"J-curve revisited. Lancet, The, 1996, 348, 696-697.	6.3	28
335	Meta-Analysis of effectiveness or lack thereof of Angiotensin-Converting enzyme inhibitors for prevention of heart failure in patients with systemic hypertension. American Journal of Cardiology, 2004, 93, 240-243.	0.7	28
336	Reference Values for the Arterial Pulse Wave in Chinese. American Journal of Hypertension, 2008, 21, 668-673.	1.0	28
337	Are blood pressure and diabetes additive or synergistic risk factors? Outcome in 8494 subjects randomly recruited from 10 populations. Hypertension Research, 2011, 34, 714-721.	1.5	28
338	Doppler indexes of left ventricular systolic and diastolic function in relation to the arterial stiffness in a general population. Journal of Hypertension, 2016, 34, 762-771.	0.3	28
339	Does Antihypertensive Drug Class Affect Dayâ€toâ€Day Variability of Selfâ€Measured Home Blood Pressure? The HOMEDâ€BP Study. Journal of the American Heart Association, 2016, 5, e002995.	1.6	28
340	Office blood pressure measurement in the 21st century. Journal of Clinical Hypertension, 2018, 20, 1104-1107.	1.0	28
341	A urinary peptidomic profile predicts outcome in SARS-CoV-2-infected patients. EClinicalMedicine, 2021, 36, 100883.	3.2	28
342	Adducin and hypertension. Pharmacogenomics, 2005, 6, 665-669.	0.6	27

#	Article	IF	CITATIONS
343	Blood Pressure Variability Remains an Elusive Predictor of Cardiovascular Outcome. American Journal of Hypertension, 2009, 22, 3-4.	1.0	27
344	Incidence of nephrolithiasis in relation to environmental exposure to lead and cadmium in a population study. Environmental Research, 2016, 145, 1-8.	3.7	27
345	Does Extremely Low Birth Weight Predispose to Low-Renin Hypertension?. Hypertension, 2017, 69, 443-449.	1.3	27
346	Glomerular function in relation to circulating adhesion molecules and inflammation markers in a general population. Nephrology Dialysis Transplantation, 2018, 33, 426-435.	0.4	27
347	Benefits of Antihypertensive Pharmacologic Therapy and Blood Pressure Reduction in Outcome Trials. Journal of Clinical Hypertension, 2003, 5, 66-75.	1.0	26
348	â~'391 C to G substitution in the regulator of G-protein signalling-2 promoter increases susceptibility to the metabolic syndrome in white European men: consistency between molecular and epidemiological studies. Journal of Hypertension, 2007, 25, 117-125.	0.3	26
349	Diagnostic thresholds for ambulatory blood pressure monitoring based on 10-year cardiovascular risk. Blood Pressure Monitoring, 2007, 12, 393-395.	0.4	26
350	The association of waist circumference with ambulatory blood pressure is independent of alternative adiposity indices. Journal of Hypertension, 2007, 25, 1798-1806.	0.3	26
351	Insulin Resistance in Relation to Lipids and Inflammation in Type-2 Diabetic Patients and Non-Diabetic People. PLoS ONE, 2016, 11, e0153171.	1.1	26
352	Short report. Journal of Hypertension, 1993, 11, 1289???1298.	0.3	25
353	Quality of life on randomized treatment for isolated systolic hypertension: results from the Syst-Eur Trial. Journal of Hypertension, 2002, 20, 2069-2079.	0.3	25
354	Relationship between left ventricular mass and the ACE D/I polymorphism varies according to sodium intake. Journal of Hypertension, 2004, 22, 287-295.	0.3	25
355	Interaction Between Body Mass Index and Alcohol Intake in Relation to Blood Pressure in HAN and SHE Chinese. American Journal of Hypertension, 2006, 19, 448-453.	1.0	25
356	Age dependency of central and peripheral systolic blood pressures: Cross-sectional and longitudinal observations in European populations. Blood Pressure, 2012, 21, 58-68.	0.7	25
357	Renal denervation in treatment-resistant hypertension: the need for restraint and more and better evidence. Expert Review of Cardiovascular Therapy, 2013, 11, 739-749.	0.6	25
358	Variation of PEAR1 DNA methylation influences platelet and leukocyte function. Clinical Epigenetics, 2019, 11, 151.	1.8	25
359	Does B-mode common carotid artery intima-media thickness differ from M-model?. Ultrasound in Medicine and Biology, 2001, 27, 1333-1336.	0.7	24
360	How to use home blood pressure monitors in clinical practice. American Journal of Hypertension, 2002, 15, 93-96.	1.0	24

#	Article	IF	CITATIONS
361	Phenotyping the Microcirculation. Hypertension, 2012, 60, 523-527.	1.3	24
362	Characteristics and Determinants of the Sublingual Microcirculation in Populations of Different Ethnicity. Hypertension, 2015, 65, 993-1001.	1.3	24
363	A Urinary Fragment of Mucin-1 Subunit $\hat{l}\pm$ Is a Novel Biomarker Associated With Renal Dysfunction in the General Population. Kidney International Reports, 2017, 2, 811-820.	0.4	24
364	Diagnosis and management of resistant hypertension: state of the art. Nature Reviews Nephrology, 2018, 14, 428-441.	4.1	24
365	Association of Fatal and Nonfatal Cardiovascular Outcomes With 24-Hour Mean Arterial Pressure. Hypertension, 2021, 77, 39-48.	1.3	24
366	Peripheral blood mitochondrial DNA content in relation to circulating metabolites and inflammatory markers: A population study. PLoS ONE, 2017, 12, e0181036.	1.1	24
367	Heart â€~omics' in AGEing (HOMAGE): design, research objectives and characteristics of the common database. Journal of Biomedical Research, 2014, 28, 349.	0.7	24
368	Blood pressure phenotypes in relation to the ??-adducin C1797T polymorphism in the European Project on Genes in Hypertension(EPOGH). Blood Pressure Monitoring, 2003, 8, 151-154.	0.4	23
369	Alcohol intake modulates the genetic association between HDL cholesterol and the PPAR \hat{I}^3 2 Pro12Ala polymorphism. Journal of Lipid Research, 2005, 46, 913-919.	2.0	23
370	Sodium excretion as a modulator of genetic associations with cardiovascular phenotypes in the European Project on Genes in Hypertension. Journal of Hypertension, 2006, 24, 235-242.	0.3	23
371	Fetuin-A and arterial stiffness in patients with normal kidney function. Regulatory Peptides, 2009, 154, 39-43.	1.9	23
372	Short-term blood pressure variability in relation to outcome in the International Database of Ambulatory blood pressure in relation to Cardiovascular Outcome (IDACO). Acta Cardiologica, 2011, 66, 701-706.	0.3	23
373	Patterns of ambulatory blood pressure: clinical relevance and application. Journal of Clinical Hypertension, 2018, 20, 1112-1115.	1.0	23
374	Outcome-Driven Thresholds for Ambulatory Blood Pressure Based on the New American College of Cardiology/American Heart Association Classification of Hypertension. Hypertension, 2019, 74, 776-783.	1.3	23
375	Diastolic left ventricular function in relation to circulating metabolic biomarkers in a population study. European Journal of Preventive Cardiology, 2019, 26, 22-32.	0.8	23
376	Prevalence, pathophysiology and treatment of isolated systolic hypertension in the elderly. Expert Review of Cardiovascular Therapy, 2004, 2, 761-769.	0.6	22
377	Association Between Arterial Properties and Renal Sodium Handling in a General Population. Hypertension, 2006, 48, 609-615.	1.3	22
378	The Trough-to-Peak Ratio as an Instrument to Evaluate Antihypertensive Drugs. Hypertension, 1995, 26, 942-949.	1.3	22

#	Article	IF	Citations
379	Ambulatory Monitoring Uncorrected for Placebo Overestimates Long-term Antihypertensive Action. Hypertension, 1996, 27, 414-420.	1.3	22
380	Diastolic Left Ventricular Function in Relation to Urinary and Serum Collagen Biomarkers in a General Population. PLoS ONE, 2016, 11, e0167582.	1.1	22
381	Relationship Between Treatment-Induced Changes in Left Ventricular Mass and Blood Pressure in Black African Hypertensive Patients. Circulation, 2002, 105, 830-836.	1.6	21
382	Blood pressure, serum total cholesterol and contraceptive pill use in 17-year-old girls. European Journal of Cardiovascular Prevention and Rehabilitation, 2003, 10, 438-442.	3.1	21
383	Maternal and Paternal Influences on Left Ventricular Mass of Offspring. Hypertension, 2003, 41, 69-74.	1.3	21
384	Relationship between ambulatory blood pressure and follow-up clinic blood pressure in elderly patients with systolic hypertension. Journal of Hypertension, 2004, 22, 81-87.	0.3	21
385	Isolated nocturnal hypertension and arterial stiffness in a Chinese population. Blood Pressure Monitoring, 2008, 13, 157-159.	0.4	21
386	Responses of the ambulatory arterial stiffness index and other measures of arterial function to antihypertensive drugs. Hypertension Research, 2011, 34, 489-495.	1.5	21
387	Association of left ventricular mass with the AGTR1 A1166C polymorphism. American Journal of Hypertension, 2012, 25, 472-478.	1.0	21
388	Thresholds for Conventional and Home Blood Pressure by Sex and Age in 5018 Participants From 5 Populations. Hypertension, 2014, 64, 695-701.	1.3	21
389	Ambulatory blood pressure and long-term risk for atrial fibrillation. Heart, 2018, 104, 1263-1270.	1.2	21
390	Brachial–ankle pulse wave velocity compared with mean arterial pressure and pulse pressure in risk stratification in a Chinese population. Journal of Hypertension, 2018, 36, 528-536.	0.3	21
391	Dementia and antihypertensive treatment. Current Opinion in Nephrology and Hypertension, 2004, 13, 225-230.	1.0	20
392	Reproducibility of the ambulatory arterial stiffness index in hypertensive patients. Journal of Hypertension, 2008, 26, 1993-2000.	0.3	20
393	Conventional and Ambulatory Blood Pressure as Predictors of Retinal Arteriolar Narrowing. Hypertension, 2016, 68, 511-520.	1.3	20
394	The Diurnal Profile of Central Hemodynamics in a General Uruguayan Population. American Journal of Hypertension, 2016, 29, 737-746.	1.0	20
395	Results of a randomized controlled pilot trial of intravascular renal denervation for management of treatment-resistant hypertension. Blood Pressure, 2017, 26, 321-331.	0.7	20
396	A population-based approach to assess the heritability and distribution of renal handling of electrolytes. Kidney International, 2017, 92, 1536-1543.	2.6	20

#	Article	IF	CITATIONS
397	Genetics of ion homeostasis in Ménière's Disease. European Archives of Oto-Rhino-Laryngology, 2017, 274, 757-763.	0.8	20
398	Epidemiologic observations guiding clinical application of a urinary peptidomic marker of diastolic left ventricular dysfunction. Journal of the American Society of Hypertension, 2018, 12, 438-447.e4.	2.3	20
399	Association between cognition and the retinal microvasculature in 11-year old children born preterm or at term. Early Human Development, 2018, 118, 1-7.	0.8	20
400	Blood pressure response to renal denervation is correlated with baseline blood pressure variability. Journal of Hypertension, 2018, 36, 221-229.	0.3	20
401	Impact of psychological profile on drug adherence and drug resistance in patients with apparently treatment-resistant hypertension. Blood Pressure, 2018, 27, 358-367.	0.7	20
402	Blood pressure measurement in special populations and circumstances. Journal of Clinical Hypertension, 2018, 20, 1122-1127.	1.0	20
403	Cardiac Microvascular Endothelial Cells in Pressure Overload–Induced Heart Disease. Circulation: Heart Failure, 2021, 14, e006979.	1.6	20
404	Determining the Trough-to-Peak Ratio in Parallel-Group Trials. Hypertension, 1997, 29, 659-667.	1.3	20
405	Short report: Low-level lead exposure does not increase the blood pressure in the general population. Journal of Hypertension, 1993, 11, 589-593.	0.3	19
406	Pharmacogenomics of primary hypertension – the lessons from the past to look toward the future. Pharmacogenomics, 2003, 4, 279-296.	0.6	19
407	Is blood pressure during the night more predictive of cardiovascular outcome than during the day?. Blood Pressure Monitoring, 2008, 13, 145-147.	0.4	19
408	Design and feasibility of "PREMATurity as predictor of children's Cardiovascular–renal Health― (PREMATCH): A pilot study. Blood Pressure, 2015, 24, 275-283.	0.7	19
409	Risk Stratification by Cross-Classification of Central and Brachial Systolic Blood Pressure. Hypertension, 2022, 79, 1101-1111.	1.3	19
410	Hypertension Caused by Low-Level Lead Exposure: Myth or Fact?. European Journal of Cardiovascular Prevention and Rehabilitation, 1994, 1, 87-97.	3.1	18
411	Benefit of antihypertensive treatment in the diabetic patients enrolled in the Systolic Hypertension in Europe (Syst-Eur) trial. Cardiovascular Drugs and Therapy, 2000, 14, 49-53.	1.3	18
412	Risk and benefit of treatment of isolated systolic hypertension in the elderly: evidence from the Systolic Hypertension in Europe Trial. Current Opinion in Cardiology, 2001, 16, 342-348.	0.8	18
413	Comparison of conventional and automated blood pressure measurements: interim analysis of the THOP trial. Blood Pressure Monitoring, 2002, 7, 61-62.	0.4	18
414	Isolated systolic hypertension and the risk of vascular disease. Current Hypertension Reports, 2003, 5, 372-379.	1.5	18

#	Article	IF	CITATIONS
415	Cardiovascular and metabolic phenotypes in relation to the ADRA2B insertion/deletion polymorphism in a Chinese population. Journal of Hypertension, 2005, 23, 2201-2207.	0.3	18
416	Is "Usual" Blood Pressure a Proxy for 24-h Ambulatory Blood Pressure in Predicting Cardiovascular Outcomes?. American Journal of Hypertension, 2008, 21, 994-1000.	1.0	18
417	Heritability of left ventricular structure and function in Caucasian families. European Heart Journal Cardiovascular Imaging, 2011, 12, 326-332.	0.5	18
418	Reducing Salt Intake for Prevention of Cardiovascular Diseaseâ€"Times Are Changing. Advances in Chronic Kidney Disease, 2015, 22, 108-115.	0.6	18
419	Relationship between office and home blood pressure with increasing age: The International Database of HOme blood pressure in relation to Cardiovascular Outcome (IDHOCO). Hypertension Research, 2016, 39, 612-617.	1.5	18
420	Associations of plasma uric acid and purine metabolites with blood pressure in children. Journal of Hypertension, 2017, 35, 982-993.	0.3	18
421	VALUE: analysis of results. Lancet, The, 2004, 364, 931.	6.3	17
422	OASIS-HT: design of a pharmacogenomic dose-finding study. Pharmacogenomics, 2005, 6, 755-775.	0.6	17
423	Fracture risk and the use of a diuretic (indapamide sr) \hat{A}_{\pm} perindopril: a substudy of the Hypertension in the Very Elderly Trial (HYVET). Trials, 2006, 7, 33.	0.7	17
424	Compared With Whom?. Hypertension, 2006, 47, 820-821.	1.3	17
425	Altered Molecular Weight Forms of Adiponectin in Hypertension. Journal of Clinical Hypertension, 2009, 11, 11-16.	1.0	17
426	Heritability of The Retinal Microcirculation in Flemish Families. American Journal of Hypertension, 2013, 26, 392-399.	1.0	17
427	Central Systolic Augmentation Indexes and Urinary Sodium in a White Population. American Journal of Hypertension, 2013, 26, 95-103.	1.0	17
428	Risk Stratification by 24-Hour Ambulatory Blood Pressure and Estimated Glomerular Filtration Rate in 5322 Subjects From 11 Populations. Hypertension, 2013, 61, 18-26.	1.3	17
429	Blood pressure variability in risk stratification: What does it add?. Clinical and Experimental Pharmacology and Physiology, 2014, 41, 1-8.	0.9	17
430	Does blood pressure variability contribute to risk stratification? Methodological issues and a review of outcome studies based on home blood pressure. Hypertension Research, 2015, 38, 97-101.	1.5	17
431	Associations of Urinary Caffeine and Caffeine Metabolites With Arterial Stiffness in a Large Population-Based Study. Mayo Clinic Proceedings, 2018, 93, 586-596.	1.4	17
432	Inactive matrix Gla protein is a novel circulating biomarker predicting retinal arteriolar narrowing in humans. Scientific Reports, 2018, 8, 15088.	1.6	17

#	Article	IF	CITATIONS
433	Urinary Peptidomic Biomarker for Personalized Prevention and Treatment of Diastolic Left Ventricular Dysfunction. Proteomics - Clinical Applications, 2019, 13, 1800174.	0.8	17
434	Urinary peptidomic profiles to address age-related disabilities: a prospective population study. The Lancet Healthy Longevity, 2021, 2, e690-e703.	2.0	17
435	Is a positive association between lead exposure and blood pressure supported by animal experiments?. Current Opinion in Nephrology and Hypertension, 1994, 3, 257-263.	1.0	16
436	Prevention of dementia: Syst-Eur trial. Lancet, The, 1999, 353, 236-237.	6.3	16
437	Amlodipine Better Than Lisinopril?. Hypertension, 2006, 48, 359-361.	1.3	16
438	Effects of genetic variation in adducin on left ventricular diastolic function as assessed by tissue Doppler imaging in a Flemish population. Journal of Hypertension, 2008, 26, 1229-1236.	0.3	16
439	Retinal arteriolar and venular phenotypes in a Flemish population: Reproducibility and correlates. Artery Research, 2011, 5, 72.	0.3	16
440	Residual Effect of Renal Denervation in Patients With Truly Resistant Hypertension. Hypertension, 2013, 62, 450-452.	1.3	16
441	Cardiovascular drugs and cancer: of competing risk, smallpox, Bernoulli, and d'Alembert. European Heart Journal, 2013, 34, 1095-1098.	1.0	16
442	Association of digital vascular function with cardiovascular risk factors: a population study. BMJ Open, 2014, 4, e004399.	0.8	16
443	Cytokines profile in hypertensive patients with left ventricular remodeling and dysfunction. Journal of the American Society of Hypertension, 2015, 9, 975-984.e3.	2.3	16
444	Diastolic Left Ventricular Function in Relation to Circulating Metabolic Biomarkers in a General Population. Journal of the American Heart Association, 2016, 5, e002681.	1.6	16
445	Temporal changes in left ventricular longitudinal strain in general population: Clinical correlates and impact on cardiac remodeling. Echocardiography, 2019, 36, 458-468.	0.3	16
446	A novel urinary biomarker predicts 1-year mortality after discharge from intensive care. Critical Care, 2020, 24, 10.	2.5	16
447	Visit-to-Visit Blood Pressure Variability and Clinical Outcomes in Patients With Heart Failure With Preserved Ejection Fraction. Hypertension, 2021, 77, 1549-1558.	1.3	16
448	CD99 and polymeric immunoglobulin receptor peptides deregulation in critical COVIDâ€19: A potential link to molecular pathophysiology?. Proteomics, 2021, 21, e2100133.	1.3	16
449	Isolated Diastolic Hypertension in the IDACO Study: An Age-Stratified Analysis Using 24-Hour Ambulatory Blood Pressure Measurements. Hypertension, 2021, 78, 1222-1231.	1.3	16
450	Associations of orthostatic blood pressure fall in older patients with isolated systolic hypertension. Journal of Hypertension, 1996, 14, 943???950.	0.3	15

#	Article	IF	CITATIONS
451	Ambulatory Blood Pressure: Normality and Comparison With Other Measurements. Hypertension, 2000, 35, E8.	1.3	15
452	Critical appraisal of the JNC VI, WHO/ISH and BHS guidelines for essential hypertension. Expert Opinion on Pharmacotherapy, 2000, $1,675-682$.	0.9	15
453	The benefit of treating isolated systolic hypertension. Current Hypertension Reports, 2001, 3, 333-339.	1.5	15
454	Rationale and design of the Investigator-Steered Project on intravascular Renal Denervation for Management of Drug-Resistant Hypertension (INSPIRED) trial. Blood Pressure, 2014, 23, 138-146.	0.7	15
455	Retinal microvascular diameter, a hypertension-related trait, in ECG-gated vs. non-gated images analyzed by IVAN and SIVA. Hypertension Research, 2016, 39, 886-892.	1.5	15
456	Flow-mediated slowing of brachial-radial pulse wave velocity: Methodological aspects and clinical determinants. Artery Research, 2018, 21, 29.	0.3	15
457	The risk of nephrolithiasis is causally related to inactive matrix Gla protein, a marker of vitamin K status: a Mendelian randomization study in a Flemish population. Nephrology Dialysis Transplantation, 2018, 33, 514-522.	0.4	15
458	Extremely Low Birth Weight Predisposes to Impaired Renal Health: A Pooled Analysis. Kidney and Blood Pressure Research, 2019, 44, 897-906.	0.9	15
459	Antihypertensive treatment guided by genetics: PEARL-HT, the randomized proof-of-concept trial comparing rostafuroxin with losartan. Pharmacogenomics Journal, 2021, 21, 346-358.	0.9	15
460	Relative and Absolute Risk to Guide the Management of Pulse Pressure, an Age-Related Cardiovascular Risk Factor. American Journal of Hypertension, 2021, 34, 929-938.	1.0	15
461	Dipping Deeper Into the Ambulatory Arterial Stiffness Index. Hypertension, 2007, 50, e59-60; author reply e61-2.	1.3	14
462	Sum and substance in the Jikei Heart Study. Lancet, The, 2007, 369, 1407-1408.	6.3	14
463	Reference frame for home pulse pressure based on cardiovascular risk in 6470 subjects from 5 populations. Hypertension Research, 2014, 37, 672-678.	1.5	14
464	STK39 and WNK1 Are Potential Hypertension Susceptibility Genes in the BELHYPGEN Cohort. Medicine (United States), 2016, 95, e2968.	0.4	14
465	Renal glomerular dysfunction in relation to retinal arteriolar narrowing and high pulse pressure in seniors. Hypertension Research, 2016, 39, 138-143.	1.5	14
466	Association of office and ambulatory blood pressure with blood lead in workers before occupational exposure. Journal of the American Society of Hypertension, 2018, 12, 14-24.	2.3	14
467	Blood Pressure in relation to 24-Hour Urinary Sodium and Potassium Excretion in a Uruguayan Population Sample. International Journal of Hypertension, 2018, 2018, 1-10.	0.5	14
468	Central Hemodynamics in Relation to Circulating Desphosphoâ€Uncarboxylated Matrix Gla Protein: A Population Study. Journal of the American Heart Association, 2019, 8, e011960.	1.6	14

#	Article	IF	CITATIONS
469	Clinical Significance of Mean and Pulse Pressure in Patients With Heart Failure With Preserved Ejection Fraction. Hypertension, 2022, 79, 241-250.	1.3	14
470	Implications of the Systolic Hypertension in China Trial. Clinical and Experimental Hypertension, 1999, 21, 499-505.	0.5	13
471	Prevalence of hypertension, hypercholesterolemia, smoking and overweight in older Belgian adolescents. European Journal of Public Health, 2004, 14, 361-365.	0.1	13
472	Left ventricular geometry and endogenous ouabain in a Flemish population. Journal of Hypertension, 2009, 27, 1884-1891.	0.3	13
473	Relationship between maternal gestational hypertension and home blood pressure in 7-year-old children and their mothers: Tohoku Study of Child Development. Hypertension Research, 2015, 38, 776-782.	1.5	13
474	Vitamin-K-Dependent Protection of the Renal Microvasculature: Histopathological Studies in Normal and Diseased Kidneys. Pulse, 2016, 4, 85-91.	0.9	13
475	Prevalence and Determinants of Masked Hypertension Among Black Nigerians Compared With a Reference Population. Hypertension, 2016, 67, 1249-1255.	1.3	13
476	Independent effects of blood pressure and parathyroid hormone on aortic pulse wave velocity in untreated Chinese patients. Journal of Hypertension, 2017, 35, 1841-1848.	0.3	13
477	PEAR1 is not a major susceptibility gene for cardiovascular disease in a Flemish population. BMC Medical Genetics, 2017, 18, 45.	2.1	13
478	Interpretation of Population Health Metrics. Hypertension, 2020, 75, 603-614.	1.3	13
479	Trough-To-Peak Versus Surface Ratio in the Assessment of Antihypertensive Agents. Blood Pressure, 1995, 4, 350-357.	0.7	12
480	Detection of Cerebral Aging, an Absolute Need: Predictive Valueof Cognitive Status. European Neurology, 1998, 39, 2-6.	0.6	12
481	Blood Pressure–Measuring Devices. Hypertension, 2000, 35, 1037-1037.	1.3	12
482	How well can blood pressure be controlled? Progress report on the Systolic Hypertension in Europe Follow-Up Study (Syst-Eur 2). Current Controlled Trials in Cardiovascular Medicine, 2001, 2, 298.	1.5	12
483	Coronary risk in relation to genetic variation in MEOX2 and TCF15 in a Flemish population. BMC Genetics, 2015, 16, 116.	2.7	12
484	Heritability of ambulatory and office blood pressure in the Swiss population. Journal of Hypertension, 2015, 33, 2061-2067.	0.3	12
485	Renal sympathetic denervation after Symplicity HTN-3 and therapeutic drug monitoring in severe hypertension. Frontiers in Physiology, 2015, 6, 9.	1.3	12
486	Study for Promotion of Health in Recycling Lead – Rationale and design. Blood Pressure, 2015, 24, 147-157.	0.7	12

#	Article	IF	CITATIONS
487	Expertise. Journal of Hypertension, 2017, 35, 1564-1566.	0.3	12
488	ECG Voltage in Relation to Peripheral and Central Ambulatory Blood Pressure. American Journal of Hypertension, 2018, 31, 178-187.	1.0	12
489	Psycho-emotional stress and salt intake may interact to raise blood pressure. European Journal of Cardiovascular Prevention and Rehabilitation, 1994, 1, 45-51.	1.5	11
490	Risks of smoking in treated and untreated older Chinese patients with isolated systolic hypertension. Journal of Hypertension, 2001, 19, 187-192.	0.3	11
491	Conventional Therapy and Newer Drug Classes for Cardiovascular Protection in Hypertension. Journal of the American Society of Nephrology: JASN, 2002, 13, S208-S215.	3.0	11
492	Rationale and methodology of monitoring ambulatory blood pressure and arterial compliance in the Hypertension in the Very Elderly Trial. Blood Pressure Monitoring, 2006, 11, 3-8.	0.4	11
493	???Beyond blood pressure??? means multiple risk factor intervention, not pleiotropic antihypertensive drugs. Current Opinion in Cardiology, 2007, 22, 335-343.	0.8	11
494	Intrafamilial Correlations of Carotid Intima–Media Thickness and Flow-Mediated Dilation in a Siberian Population. American Journal of Hypertension, 2007, 20, 248-254.	1.0	11
495	SAH gene variants revisited in the European Project On Genes in Hypertension. Journal of Hypertension, 2008, 26, 244-250.	0.3	11
496	Morbidity and mortality on combination versus monotherapy: a posthoc analysis of the Systolic Hypertension in Europe trial. Journal of Hypertension, 2010, 28, 865-874.	0.3	11
497	Estimation of Glomerular Filtration Rate Based on Serum Cystatin C versus Creatinine in a Uruguayan Population. International Journal of Nephrology, 2014, 2014, 1-9.	0.7	11
498	Persistence of Masked Hypertension in Chinese Patients. American Journal of Hypertension, 2016, 29, 326-331.	1.0	11
499	Renal denervation in treatment-resistant hypertension: a reappraisal. Current Opinion in Pharmacology, 2015, 21, 48-52.	1.7	11
500	Office and Home Blood Pressures as Determinants of Electrocardiographic Left Ventricular Hypertrophy Among Black Nigerians Compared With White Flemish. American Journal of Hypertension, 2017, 30, 1083-1092.	1.0	11
501	Management of a Pregnant Woman With Fibromuscular Dysplasia. Hypertension, 2018, 71, 540-547.	1.3	11
502	The rationale and design of reduction of uncontrolled hypertension by Remote Monitoring and Telemedicine (REMOTE) study. Blood Pressure, 2018, 27, 99-105.	0.7	11
503	Adherence to antihypertensive drug treatment in patients with apparently treatment-resistant hypertension in the INSPiRED pilot study. Blood Pressure, 2019, 28, 168-172.	0.7	11
504	Renal function in relation to low-level environmental lead exposure. Nephrology Dialysis Transplantation, 2019, 34, 941-946.	0.4	11

#	Article	IF	Citations
505	Identification of sexâ€specific biomarkers predicting newâ€onset heart failure. ESC Heart Failure, 2021, 8, 3512-3520.	1.4	11
506	Treatment of diabetic patients with hypertension. Current Hypertension Reports, 1999, 1, 225-231.	1.5	10
507	Registration of trials and protocols. Lancet, The, 2003, 362, 1009-1010.	6.3	10
508	Hypertension drug trials based on ambulatory blood pressure monitoring. Journal of Hypertension, 2003, 21, 1237-1239.	0.3	10
509	Peripheral Arterial Disease and Metals in Urine and Blood. Environmental Health Perspectives, 2005, 113, A510-1; author reply A511.	2.8	10
510	Characterization and Functional Analyses of the Human G Protein–Coupled Receptor Kinase 4 Gene Promoter. Hypertension, 2008, 52, 737-746.	1.3	10
511	Arterial Properties in Relation to Genetic Variations in the Adducin Subunits in a White Population. American Journal of Hypertension, 2009, 22, 21-26.	1.0	10
512	Association of echocardiographic left ventricular structure with the ACE D/I polymorphism: a meta-analysis. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2011, 12, 243-253.	1.0	10
513	Rationale and design of the Newer Versus Older Antihypertensive Agents in African Hypertensive Patients (NOAAH) trial. Blood Pressure, 2011, 20, 256-266.	0.7	10
514	Prognostic Significance of Home Arterial Stiffness Index Derived From Self-Measurement of Blood Pressure: The Ohasama Study. American Journal of Hypertension, 2012, 25, 67-73.	1.0	10
515	Mother-off spring aggregation in home versus conventional blood pressure in the Tohoku Study of Child Development (TSCD). Acta Cardiologica, 2012, 67, 449-456.	0.3	10
516	First-in-Man Randomized Clinical Trial of Renal Denervation for Atrial Arrhythmia Raises Concern. Journal of the American College of Cardiology, 2013, 62, e445-e446.	1.2	10
517	cGMP-Dependent Protein Kinase 1 Polymorphisms Underlie Renal Sodium Handling Impairment. Hypertension, 2013, 62, 1027-1033.	1.3	10
518	Influence of the hospital environment and presence of the physician on the white-coat effect. Journal of Hypertension, 2015, 33, 2245-2249.	0.3	10
519	Association of left ventricular structure and function with peripheral blood mitochondrial DNA content in a general population. International Journal of Cardiology, 2016, 214, 180-188.	0.8	10
520	Ibuprofen exposure in early neonatal life does not affect renal function in young adolescence. Archives of Disease in Childhood: Fetal and Neonatal Edition, 2018, 103, F107-F111.	1.4	10
521	Urinary peptidomic biomarkers of renal function in heart transplant recipients. Nephrology Dialysis Transplantation, 2019, 34, 1336-1343.	0.4	10
522	Retinal Microvasculature in Relation to Central Hemodynamics in a Flemish Population. Hypertension, 2019, 74, 606-613.	1.3	10

#	Article	IF	Citations
523	Discovery, validation and sequencing of urinary peptides for diagnosis of liver fibrosis—A multicentre study. EBioMedicine, 2020, 62, 103083.	2.7	10
524	Proteomic Biomarkers in the Cardiorenal Syndrome: Toward Deciphering Molecular Pathophysiology. American Journal of Hypertension, 2021, 34, 669-679.	1.0	10
525	Serum and urinary biomarkers of collagen typeâ€l turnover predict prognosis in patients with heart failure. Clinical and Translational Medicine, 2021, 11, e267.	1.7	10
526	Epidemiological and histological findings implicate matrix Gla protein in diastolic left ventricular dysfunction. PLoS ONE, 2018, 13, e0193967.	1.1	10
527	Aspirin use is associated with increased risk for incident heart failure: a patientâ€level pooled analysis. ESC Heart Failure, 2022, 9, 685-694.	1.4	10
528	Life Style as a Blood Pressure Determinant. Journal of the Royal Society of Medicine, 1996, 89, 484-489.	1.1	9
529	What is hypertension?. Lancet, The, 1999, 354, 594.	6.3	9
530	Dementia and statins. Lancet, The, 2001, 357, 880.	6.3	9
531	Characteristics of conventional blood pressure in studies on the predictive power of ambulatory blood pressure. Blood Pressure Monitoring, 2002, 7, 33-36.	0.4	9
532	Withdrawal from treatment in the Syst-Eur Trial. Journal of Hypertension, 2002, 20, 339-346.	0.3	9
533	Relation between left ventricular mass and systolic blood pressure at baseline in the APTH and THOP trials. Blood Pressure Monitoring, 2003, 8, 173-175.	0.4	9
534	What can be expected from optimal blood pressure control?. Journal of Hypertension, 2003, 21, S3-S9.	0.3	9
535	VALUE. Journal of Hypertension, 2004, 22, 1431-1434.	0.3	9
536	Meta-analysis of blood pressure and the CYP11B2 polymorphism highlights the need for better designed studies. Journal of Hypertension, 2007, 25, 37-39.	0.3	9
537	Urinary nitric oxide metabolites and individual blood pressure progression to overt hypertension. European Journal of Cardiovascular Prevention and Rehabilitation, 2011, 18, 656-663.	3.1	9
538	Cross-sectional and longitudinal assessment of arterial stiffening with age in European and Chinese populations. Frontiers in Physiology, 2012, 3, 209.	1.3	9
539	Progress report on the first sub-Saharan Africa trial of newer versus older antihypertensive drugs in native black patients. Trials, 2012, 13, 59.	0.7	9
540	Response to Masked Hypertension in Untreated and Treated Patients With Diabetes Mellitus: Attractive But Questionable Interpretations and Response to Is Masked Hypertension Related to Diabetes Mellitus?. Hypertension, 2013, 62, e23-5.	1.3	9

#	Article	IF	CITATIONS
541	Quality of blood pressure phenotype in the Nigerian Population Research on Environment Gene and Health. Blood Pressure Monitoring, 2014, 19, 220-225.	0.4	9
542	Quality control of the blood pressure phenotype in the Gaoyou population study. Blood Pressure, 2016, 25, 162-168.	0.7	9
543	Urinary Proteomics in Predicting Heart Transplantation Outcomes (uPROPHET)—Rationale and database description. PLoS ONE, 2017, 12, e0184443.	1.1	9
544	Urinary Proteomic Profile of Arterial Stiffness Is Associated With Mortality and Cardiovascular Outcomes. Journal of the American Heart Association, 2022, 11, e024769.	1.6	9
545	Efficacy of antihypertensive drugs given once a day. Journal of Hypertension, 1994, 12, 107???116.	0.3	8
546	Benefits of antihypertensive drug treatment in elderly patients with isolated systolic hypertension. Netherlands Journal of Medicine, 2001, 58, 248-254.	0.6	8
547	Cognitive Impairment and Blood Pressure. Hypertension, 2004, 44, 612-613.	1.3	8
548	Association of Blood Pressure With Genetic Variation in WNKKinases in a White European Population. Circulation, 2005, 112, 3371-3372.	1.6	8
549	Antihypertensives for prevention of Alzheimer's disease. Lancet Neurology, The, 2006, 5, 466-468.	4.9	8
550	Is Arterial Stiffness Related to Body Height?. Hypertension, 2010, 55, e24-5.	1.3	8
551	Are Retinal Microvascular Phenotypes Associated With the 1675G/A Polymorphism in the Angiotensin II Type-2 Receptor Gene?. American Journal of Hypertension, 2011, 24, 1300-1305.	1.0	8
552	Evaluating home blood pressure in treated hypertensives in comparison with the referential value of casual screening of blood pressure. Blood Pressure Monitoring, 2012, 17, 89-95.	0.4	8
553	Association of left ventricular diastolic function with systolic dyssynchrony: a population study. European Heart Journal Cardiovascular Imaging, 2013, 14, 471-479.	0.5	8
554	Systematic Review of Health Outcomes in Relation to Salt Intake Highlights the Widening Divide Between Guidelines and the Evidence. American Journal of Hypertension, 2014, 27, 1138-1142.	1.0	8
555	Reproducibility of Retinal Microvascular Traits Decoded by the Singapore I Vessel Assessment Software Across the Human Age Range. American Journal of Hypertension, 2018, 31, 438-449.	1.0	8
556	Area of the pressure-strain loop during ejection as non-invasive index of left ventricular performance: a population study. Cardiovascular Ultrasound, 2019, 17, 15.	0.5	8
557	Associations of Left Ventricular Structure and Function With Blood Pressure in Heart Failure With Preserved Ejection Fraction: Analysis of the TOPCAT Trial. Journal of the American Heart Association, 2020, 9, e016009.	1.6	8
558	Urinary proteomics combined with home blood pressure telemonitoring for health care reform trial: rational and protocol. Blood Pressure, 2021, 30, 269-281.	0.7	8

#	Article	IF	Citations
559	Neurocognitive function in relation to blood lead among young men prior to chronic occupational exposure. Scandinavian Journal of Work, Environment and Health, 2019, 45, 298-307.	1.7	8
560	Serum insulin levels are associated with vulnerable plaque components in the carotid artery: the Rotterdam Study. European Journal of Endocrinology, 2020, 182, 343-350.	1.9	8
561	The novel proteomic signature for cardiac allograft vasculopathy. ESC Heart Failure, 2022, 9, 1216-1227.	1.4	8
562	Psycho-Emotional Stress and Salt Intake May Interact to Raise Blood Pressure. European Journal of Cardiovascular Prevention and Rehabilitation, 1994, 1, 45-51.	3.1	7
563	Ambulatory (AASI), but not home (HASI), arterial stiffness index is associated with aortic pulse wave velocity. Hypertension Research, 2011, 34, 402-403.	1.5	7
564	Tissue Doppler indexes of left ventricular systolic function in relation to the pulsatile and steady components of blood pressure in a general population. Journal of Hypertension, 2012, 30, 403-410.	0.3	7
565	Renal denervation in the management of resistant hypertension. Current Opinion in Nephrology and Hypertension, 2013, 22, 511-518.	1.0	7
566	Risk Associated with Pulse Pressure on Out-of-Office Blood Pressure Measurement. Pulse, 2014, 2, 42-51.	0.9	7
567	Renal sympathetic denervation after Symplicity HTN-3 and therapeutic drug monitoring in patients with resistant hypertension to improve patients' adherence. European Heart Journal - Cardiovascular Pharmacotherapy, 2015, 1, 48-56.	1.4	7
568	<i>PEAR1</i> is not a human hypertension-susceptibility gene. Blood Pressure, 2015, 24, 61-64.	0.7	7
569	Biomarkers to Assess Right Heart Pressures in Recipients of a Heart Transplant: A Proof-of-Concept Study. Transplantation Direct, 2018, 4, e346.	0.8	7
570	Starting Antihypertensive Drug Treatment With Combination Therapy. Hypertension, 2021, 77, 788-798.	1.3	7
571	Two-Year Responses of Heart Rate and Heart Rate Variability to First Occupational Lead Exposure. Hypertension, 2021, 77, 1775-1786.	1.3	7
572	Normal-tension glaucomatous optic neuropathy is related to blood pressure variability in the Maracaibo Aging Study. Hypertension Research, 2021, 44, 1105-1112.	1.5	7
573	Influence of ejection fraction on biomarker expression and response to spironolactone in people at risk of heart failure: findings from the <scp>HOMAGE</scp> trial. European Journal of Heart Failure, 2022, 24, 771-778.	2.9	7
574	Hypertension Optimal Treatment (HOT) trial. Lancet, The, 1998, 352, 573.	6.3	6
575	Improved Outcomes with Antihypertensive Medication in the Elderly with Isolated Systolic Hypertension. Drugs and Aging, 2001, 18, 345-353.	1.3	6
576	Data from the Dublin outcome study. Blood Pressure Monitoring, 2007, 12, 401-403.	0.4	6

#	Article	IF	CITATIONS
577	More Information on the Reproducibility of the Ambulatory Arterial Stiffness Index. American Journal of Hypertension, 2010, 23, 113-114.	1.0	6
578	Assessment of peripheral vascular function with photoplethysmographic pulse amplitude. Artery Research, 2011, 5, 58.	0.3	6
579	How many measurements are needed to provide reliable information in terms of the ambulatory arterial stiffness index? the Ohasama study. Hypertension Research, 2011, 34, 314-318.	1.5	6
580	Electric Nerve Stimulation to Monitor the Efficacy of Renal Denervation. Hypertension, 2013, 61, 288-289.	1.3	6
581	Renal sympathetic denervation in the aftermath of Symplicity HTN-3. Blood Pressure, 2014, 23, 256-261.	0.7	6
582	Age-specificity of blood-pressure-associated complications. Nature Reviews Cardiology, 2014, 11, 499-501.	6.1	6
583	Renal artery and parenchymal changes after renal denervation: assessment by magnetic resonance angiography. European Radiology, 2017, 27, 3934-3941.	2.3	6
584	The International Database of Central Arterial Properties for Risk Stratification: Research Objectives and Baseline Characteristics of Participants. American Journal of Hypertension, 2021, , .	1.0	6
585	Resistant hypertension. Kardiologia Polska, 2018, 76, 1031-1042.	0.3	6
586	Renal denervation: time to open Pandora's box. Swiss Medical Weekly, 2012, 142, w13638.	0.8	6
587	Opportunities of Antidiabetic Drugs in Cardiovascular Medicine. Hypertension, 2020, 76, 420-431.	1.3	6
588	Ambulatory Blood Pressure Monitoring in Clinical Trials. Annals of the New York Academy of Sciences, 1996, 783, 295-303.	1.8	5
589	Clinical trials in isolated systolic hypertension. Current Hypertension Reports, 1999, 1, 387-393.	1.5	5
590	Antihypertensive drug therapy in older patients. Current Opinion in Nephrology and Hypertension, 2001, 10, 263-269.	1.0	5
591	Hypertension and Low-Level Lead Exposure: A Scientific Issue or a Matter of Faith?. Hypertension, 2003, 42, e9; author reply e9.	1.3	5
592	Renal function in relation to three candidate genes in a Chinese population. Journal of Molecular Medicine, 2004, 82, 715-722.	1.7	5
593	Noncardiovascular Illness as Barrier to Antihypertensive Treatment. Hypertension, 2005, 46, 255-256.	1.3	5
594	Reducing blood pressure in people of different ages. BMJ: British Medical Journal, 2008, 336, 1080-1081.	2.4	5

#	Article	IF	CITATIONS
595	Putting a spin on the ambulatory arterial stiffness index. Journal of Hypertension, 2008, 26, 1266-1267.	0.3	5
596	Treatment of hypertension in the elderly in 2010 $\hat{a} \in \hat{a}$ a brief review. Expert Opinion on Pharmacotherapy, 2010, 11, 2609-2617.	0.9	5
597	Methodological issues in the assessment of cognitive decline in ONTARGET and TRANSCEND. Lancet Neurology, The, 2011, 10, 22-24.	4.9	5
598	A family-based association test to detect gene–gene interactions in the presence of linkage. European Journal of Human Genetics, 2012, 20, 973-980.	1.4	5
599	No Support for Renal Denervation in a Meta-Analysis. Journal of the American College of Cardiology, 2013, 62, 2029-2030.	1.2	5
600	Left Ventricular Radial Function Associated With Genetic Variation in the cGMP-Dependent Protein Kinase. Hypertension, 2013, 62, 1034-1039.	1.3	5
601	Characteristics of self-measured home blood pressure in a Nigerian urban community. Blood Pressure Monitoring, 2015, 20, 260-265.	0.4	5
602	Conventional and Ambulatory Blood Pressure as Predictors of Diastolic Left Ventricular Function in a Flemish Population. Journal of the American Heart Association, 2018, 7, .	1.6	5
603	Letter to editor: Blood pressure, hypertension and lead exposure. Environmental Health, 2018, 17, 16.	1.7	5
604	Retinal microcirculation and leukocyte telomere length in the general population. Scientific Reports, 2018, 8, 7095.	1.6	5
605	Implementing Automated Office Blood Pressure Measurement. Hypertension, 2019, 74, 441-449.	1.3	5
606	Renal Resistive Index Is Associated With Inactive Matrix Gla (γ arboxyglutamate) Protein in an Adult Populationâ€Based Study. Journal of the American Heart Association, 2019, 8, e013558.	1.6	5
607	Heart rate variability and peripheral nerve conduction velocity in relation to blood lead in newly hired lead workers. Occupational and Environmental Medicine, 2019, 76, 382-388.	1.3	5
608	Circulating Biomarkers Predicting Longitudinal Changes in Left Ventricular Structure and Function in a General Population. Journal of the American Heart Association, 2019, 8, e010430.	1.6	5
609	Two-Year Responses of Office and Ambulatory Blood Pressure to First Occupational Lead Exposure. Hypertension, 2020, 76, 1299-1307.	1.3	5
610	Retinal and Renal Microvasculature in Relation to Central Hemodynamics in 11‥earâ€Old Children Born Preterm or At Term. Journal of the American Heart Association, 2020, 9, e014305.	1.6	5
611	Two-year neurocognitive responses to first occupational lead exposure. Scandinavian Journal of Work, Environment and Health, 2021, 47, 233-243.	1.7	5
612	Open-Angle Glaucomatous Optic Neuropathy Is Related to Dips Rather Than Increases in the Mean Arterial Pressure Over 24-H. American Journal of Hypertension, 2022, 35, 703-714.	1.0	5

#	Article	IF	Citations
613	Dissecting the Polygenic Basis of Primary Hypertension: Identification of Key Pathway-Specific Components. Frontiers in Cardiovascular Medicine, 2022, 9, 814502.	1.1	5
614	Comparing and contrasting risk factors for heart failure in patients with and without history of myocardial infarction: data from <scp>HOMAGE</scp> and the <scp>UK</scp> Biobank. European Journal of Heart Failure, 2022, 24, 976-984.	2.9	5
615	The lowering of blood pressure after stroke. Lancet, The, 2001, 358, 1995-1996.	6.3	4
616	Ambulatory and conventional pulse pressures and mean pressures as determinants of the Sokolow-Lyon ECG voltage index in older patients with systolic hypertension. Blood Pressure Monitoring, 2001, 6, 197-202.	0.4	4
617	Convergence of atherosclerosis and Alzheimer's disease. Lancet, The, 2004, 363, 2091.	6.3	4
618	Ouabain and Serum Sodium. Hypertension, 2005, 45, e16; author reply e16-7.	1.3	4
619	Safety of calcium antagonists: More ACTION. American Journal of Medicine, 2005, 118, 1418-1420.	0.6	4
620	Response to Correlating Ambulatory Blood Pressure Measurements With Arterial Stiffness: A Conceptual Inconsistency. Hypertension, 2006, 48, .	1.3	4
621	Renin turning full circle as cardiovascular risk factor. European Heart Journal, 2007, 28, 2557-2558.	1.0	4
622	Left ventricular structure in relation to the human SAH gene in the European Project on Genes in Hypertension. Hypertension Research, 2009, 32, 145-151.	1.5	4
623	Periodontal disease and hypertension: a chicken and egg story?. Journal of Hypertension, 2010, 28, 2382-2383.	0.3	4
624	From pioneering to implementing automated blood pressure measurement in clinical practice: Thomas Pickering's legacy. Blood Pressure Monitoring, 2010, 15, 72-81.	0.4	4
625	Secondary Prevention after Ischemic Stroke. New England Journal of Medicine, 2012, 367, 675-677.	13.9	4
626	Cardiovascular risk factors among the inhabitants of an urban Congolese community: results of the VITARAA Study. IJC Metabolic & Endocrine, 2014, 4, 33-38.	0.5	4
627	Left ventricular diastolic function associated with common genetic variation in ATP12Ain a general population. BMC Medical Genetics, 2014, 15, 121.	2.1	4
628	Heritability and other determinants of left ventricular diastolic function in the family-based population study. Journal of Hypertension, 2014, 32, 1854-1861.	0.3	4
629	Letter by Jin et al Regarding Article, "Ambulatory Blood Pressure Changes After Renal Sympathetic Denervation in Patients With Resistant Hypertension― Circulation, 2014, 129, e499.	1.6	4
630	Metaâ€analysis of a continuous outcome combining individual patient data and aggregate data: a method based on simulated individual patient data. Research Synthesis Methods, 2014, 5, 322-351.	4.2	4

#	Article	IF	CITATIONS
631	Renal denervationâ€"promising data from the DENERHTN trial. Nature Reviews Nephrology, 2015, 11, 258-260.	4.1	4
632	Expertise: No Longer a Sine Qua Non for Guideline Authors?. Hypertension, 2017, 70, 235-237.	1.3	4
633	Doppler indexes of left ventricular systolic and diastolic function in relation to haemodynamic load components in a general population. Journal of Hypertension, 2018, 36, 867-875.	0.3	4
634	Central hemodynamics in relation to blood lead in young men prior to chronic occupational exposure. Blood Pressure, 2019, 28, 279-290.	0.7	4
635	Spironolactone effect on the blood pressure of patients at risk of developing heart failure: an analysis from the HOMAGE trial. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, , .	1.4	4
636	Circadian Variation of Blood Pressure in the Population at Large. , 2007, , 159-185.		4
637	Statistical reanalysis of vascular event outcomes in primary and secondary vascular prevention trials. BMC Medical Research Methodology, 2021, 21, 218.	1.4	4
638	Nigerian Population Research on Environment, Gene and Health (NIPREGH) - objectives and protocol. Journal of Biomedical Research, 2014, 28, 360.	0.7	4
639	Increased Collagen Turnover Is a Feature of Fibromuscular Dysplasia and Associated With Hypertrophic Radial Remodeling: A Pilot, Urine Proteomic Study. Hypertension, 2022, 79, 93-103.	1.3	4
640	Haematological phenotypes in relation to the C1797T \hat{l}^2 -adducin polymorphism in a Caucasian population. Clinical Science, 2003, 104, 369-376.	1.8	3
641	Added VALUE of an ancillary study on ambulatory blood pressure monitoring. Journal of Hypertension, 2007, 25, 513-515.	0.3	3
642	Sphygmomanometric and ambulatory blood pressures as forerunners of carotid and femoral intima–media thickness. Journal of Hypertension, 2009, 27, 813-821.	0.3	3
643	Cadmium from zinc smelter emission and variation in cancer incidence. European Journal of Cancer Prevention, 2012, 21, 497-498.	0.6	3
644	Left Ventricular Structure and Function in Relation to Steroid Biosynthesis Genes in a White Population. American Journal of Hypertension, 2012, 25, 986-993.	1.0	3
645	An Unusual Cause of Mineralocorticoid Hypertension. Hypertension, 2014, 64, 689-692.	1.3	3
646	Quality of the blood pressure phenotype in the GEnotipo, Fenotipo y Ambiente de la hipertensión arterial en UruguaY (GEFA-HT-UY) study. Blood Pressure Monitoring, 2014, 19, 339-345.	0.4	3
647	Renovascular Hypertension. Hypertension, 2014, 64, 1165-1168.	1.3	3
648	Hypertensive Encephalopathy and Renal Failure in a Young Man. Hypertension, 2016, 67, 6-13.	1.3	3

#	Article	IF	CITATIONS
649	Post-processing reproducibility of the structural characteristics of the common carotid artery in a Flemish population. Artery Research, 2017, 19, 9.	0.3	3
650	Urinary proteomic signatures associated with \hat{l}^2 -blockade and heart rate in heart transplant recipients. PLoS ONE, 2018, 13, e0204439.	1.1	3
651	Environmental exposure to lead: old myths never die. Lancet Public Health, The, 2018, 3, e362.	4.7	3
652	Paroxysmal Hypertension Associated With Urination. Hypertension, 2019, 74, 1068-1074.	1.3	3
653	The association of calcium channel blockers with $\hat{l}^2 \hat{a} \in \mathbb{C}$ ell function in type 2 diabetic patients: A cross $\hat{a} \in \mathbb{C}$ cross $\hat{a} \in \mathbb{C}$ cross $\hat{a} \in \mathbb{C}$ for a sudy. Journal of Clinical Hypertension, 2019, 21, 638-647.	1.0	3
654	Central hemodynamics in relation to low-level environmental lead exposure. Blood Pressure, 2020, 29, 157-167.	0.7	3
655	Glomerular function in relation to fine airborne particulate matter in a representative population sample. Scientific Reports, 2021, 11, 14646.	1.6	3
656	Genome-Wide Association Study to Identify Common Variants Associated with Brachial Circumference: A Meta-Analysis of 14 Cohorts. PLoS ONE, 2012, 7, e31369.	1.1	3
657	Two-Year Responses of Renal Function to First Occupational Lead Exposure. Kidney International Reports, 2022, , .	0.4	3
658	Hypertension and Lead Exposure. JAMA - Journal of the American Medical Association, 1996, 276, 1037.	3.8	2
659	Treatment of isolated systolic hypertension in the elderly: evidence from three clinical trials. European Journal of Internal Medicine, 1999, 10, 82-87.	1.0	2
660	Delayed sexual development in adolescents. Lancet, The, 2001, 358, 1817.	6.3	2
661	Risk reduction for stroke and coronary events. Lancet, The, 2002, 359, 1250-1251.	6.3	2
662	Editorial Comment—Blood Pressure Lowering for the Secondary Prevention of Stroke: One Size Fits All?. Stroke, 2003, 34, 2590-2592.	1.0	2
663	Will generic hypertension guidelines reduce the proliferation of directives?. Heart, 2007, 93, 775-777.	1.2	2
664	Context Dependency of Serum and Urinary Lithium: Implications for Measurement of Proximal Sodium Reabsorption. Hypertension, 2007, 49, e34.	1.3	2
665	Imidapril. Drugs, 2007, 67, 1379-1382.	4.9	2
666	Modulation of genetic cardiovascular risk by age and lifestyle. Current Cardiovascular Risk Reports, 2008, 2, 398-404.	0.8	2

#	Article	IF	CITATIONS
667	Determinants of arterial properties in Chinese type-2 diabetic patients compared with population-based controls. Acta Cardiologica, 2011, 66, 619-626.	0.3	2
668	Response to Letter Regarding Article, "Circulating MicroRNA-208b and MicroRNA-499 Reflect Myocardial Damage in Cardiovascular Disease― Circulation: Cardiovascular Genetics, 2011, 4, .	5.1	2
669	Quality of Life After Renal Denervation. Hypertension, 2013, 61, e38.	1.3	2
670	Central vs. peripheral blood pressure components as determinants of retinal microvessel diameters. Artery Research, 2013, 8, 35.	0.3	2
671	Response to HYVET Ambulatory Blood Pressure Substudy. Hypertension, 2013, 61, e43.	1.3	2
672	Con: Renal denervation for all resistant hypertensive patients: the Emperor's new clothes. Nephrology Dialysis Transplantation, 2014, 29, 1116-1119.	0.4	2
673	Heart rate variability on antihypertensive drugs in black patients living in sub-Saharan Africa. Blood Pressure, 2014, 23, 174-180.	0.7	2
674	Will Sodium Intake Reduction Improve Cardiovascular Outcomes in the General Population? A Critical Review of Current Evidence. Current Hypertension Reviews, 2015, 11, 22-29.	0.5	2
675	Alpha-1 antitrypsin deficiency. Journal of Hypertension, 2016, 34, 1659-1661.	0.3	2
676	A Woman With Treatment-Resistant Hypertension. Hypertension, 2016, 67, 243-250.	1.3	2
677	Reply. Journal of the American College of Cardiology, 2017, 69, 2880-2881.	1.2	2
678	Genome-wide association study for white coat effect in Japanese middle-aged to elderly people: The HOMED-BP study. Clinical and Experimental Hypertension, 2018, 40, 363-369.	0.5	2
679	How to reliably diagnose arterial hypertension: lessons from 24 h blood pressure monitoring. Blood Pressure, 2019, 28, 93-98.	0.7	2
680	Electrocardiographic left ventricular hypertrophy in relation to peripheral and central blood pressure indices in a Nigerian population. Blood Pressure, 2020, 29, 39-46.	0.7	2
681	Sex-Specific Associations of Risks and Cardiac Structure and Function With Microalbumin/Creatinine Ratio in Diastolic Heart Failure. Frontiers in Cardiovascular Medicine, 2020, 7, 579400.	1.1	2
682	Sex differences in the longitudinal relationship of low-grade inflammation and echocardiographic measures in the Hoorn and FLEMENGHO Study. PLoS ONE, 2021, 16, e0251148.	1.1	2
683	Investigating the Relations Between Caffeine-Derived Metabolites and Plasma Lipids in 2 Population-Based Studies. Mayo Clinic Proceedings, 2021, 96, 3071-3085.	1.4	2
684	Should high-normal blood pressure be treated?. Journal of Hypertension, 2002, 20, 1028-1030.	0.3	2

#	Article	IF	CITATIONS
685	Renal Denervation After Symplicity HTN-3 $\hat{a}\in$ Back to Basics. Review of the Evidence. European Cardiology Review, 2014, 9, 110.	0.7	2
686	ANTIHYPERTENSIVE DRUGS AND COGNITIVE FUNCTION IN OLDER PEOPLE. Journal of the American Geriatrics Society, 1998, 46, 791-791.	1.3	1
687	What does STOP-2 tell us about management of hypertension?. Lancet, The, 2000, 355, 651.	6.3	1
688	A plea for harmonising guidelines. International Journal of Cardiology, 2001, 79, 129-132.	0.8	1
689	Hormonal regulation of human adipocytes at the cross-roads between obesity and hypertension. Journal of Hypertension, 2002, 20, 839-841.	0.3	1
690	Haematological phenotypes in relation to the C1797T \hat{l}^2 -adducin polymorphism in a Caucasian population. Clinical Science, 2003, 104, 369.	1.8	1
691	Spotlights on Ambulatory Measures of Arterial Stiffness. American Journal of Hypertension, 2008, 21, 368-369.	1.0	1
692	Wave Reflection in Systolic Hypertension: Smaller Stature, Shorter Aorta: Higher Pulse Pressure?. Hypertension, 2008, 51, e37; author reply e39-40.	1.3	1
693	Candesartan for cardiovascular prevention in Japanese hypertensive patients with coronary heart disease. European Heart Journal, 2009, 30, 1164-1166.	1.0	1
694	Cardiovascular effects of tight versus usual blood-pressure control – Authors' reply. Lancet, The, 2009, 374, 1742.	6.3	1
695	Maximum or Mean: That Is the Question. Hypertension, 2011, 58, e13-4; author reply e15.	1.3	1
696	Does Pseudoresistant Hypertension Attributed to White-Coat Effect Define Subjects With "Treated Normalized Hypertension?― Hypertension, 2012, 59, e43; author reply e44.	1.3	1
697	Central haemodynamics reveal significant potential for prevention in Black hypertensive patients born and living in sub-Saharan Africa. Artery Research, 2012, 6, 41.	0.3	1
698	Left ventricular mass in relation to midlife blood pressure. European Heart Journal, 2014, 35, 3242-3244.	1.0	1
699	Denervation of Native Kidneys in a Renal Transplant Recipient: One Swallow Does Not Make a Spring. American Journal of Hypertension, 2014, 27, 897-898.	1.0	1
700	Dynamic Interaction Between Micro- and Macro-Circulation: A Concept With Feet of Clay. American Journal of Hypertension, 2015, 28, 693-694.	1.0	1
701	Blood Pressure Variability as Elusive Harbinger of Adverse Health Outcomes. , 2016, , 129-148.		1
702	Association of pulse wave velocity with single nucleotide polymorphisms related to parathyroid hormone. Blood Pressure, 2018, 27, 222-230.	0.7	1

#	Article	IF	Citations
703	Diagnosis and Management of Resistant Hypertension. Hypertension, 2019, 74, 1064-1067.	1.3	1
704	Blood Pressure Indexes Associated With Mortality and Cardiovascular Outcomesâ€"Reply. JAMA - Journal of the American Medical Association, 2019, 322, 2343.	3.8	1
705	Do clinical trial data suggest a role for SGLT2-inhibitors in primary prevention of heart failure and chronic kidney disease?. International Journal of Cardiology Cardiovascular Risk and Prevention, 2021, 10, 200100.	0.4	1
706	Circadian Variation of the Blood Pressure in the Population at Large., 2001, , 139-158.		1
707	Leuven Consensus Conference on Ambulatory Blood Pressure Monitoring in commemoration of Professor Dr A. Amery (†2 November 1994) 23–25 September 1999. Blood Pressure Monitoring, 1999, 4, 277-278.	0.4	1
708	SYMPLICITY HTN-3 results to be announced: a mystery or a story foretold? Journal of Biomedical Research, 2014, 28, 73.	0.7	1
709	Association of colorectal cancer with genetic and epigenetic variation in PEAR1—A population-based cohort study. PLoS ONE, 2022, 17, e0266481.	1.1	1
710	QTc intervals are not prolonged in former ELBW infants at pre-adolescent age. Pediatric Research, 2022, 92, 848-852.	1.1	1
711	Participation rate in the Belgian population study on ambulatory blood pressure monitoring. Journal of Hypertension, 1996, 14, 1257.	0.3	0
712	Treatment of hypertension in elderly patients. Lancet, The, 1997, 350, 1634.	6.3	0
713	Prevalence of hypertension and other cardiovascular risk factors in 17-18-year old Belgian adolescents. American Journal of Hypertension, 2001, 14, A244.	1.0	0
714	Subgroup analysis of the NORDIL trial. Journal of Hypertension, 2002, 20, 1085-1087.	0.3	0
715	Ambulatory pulse pressure as predictor of outcome in older patients with systolic hypertension. American Journal of Hypertension, 2002, 15, A27.	1.0	0
716	Ongoing trials: What should we expect after ALLHAT?. Current Hypertension Reports, 2003, 5, 340-345.	1.5	0
717	Antihypertensive treatment based on conventional or home blood pressure measurement - the thop trial. American Journal of Hypertension, 2003, 16, A63.	1.0	0
718	Salt, endogenous ouabain and blood pressure interactions in the general population. American Journal of Hypertension, 2003, 16, A170.	1.0	0
719	ls angiogenesis a plausible hypothesis in Alzheimer's disease?. Journal of Hypertension, 2003, 21, 1426-1427.	0.3	0
720	Design of the Syst-Eur trial and Syst-Eur Phase 2. Journal of Hypertension, 2004, 22, 1631-1632.	0.3	0

#	Article	IF	CITATIONS
721	Cardiovascular Outcomes and Antihypertensive Drug Treatment in Older Women. JAMA - Journal of the American Medical Association, 2005, 293, 1588.	3.8	O
722	Sodium excretion as a modulator of genetic influence on arterial stiffness and other cardiovascular phenotypes. Artery Research, 2007, 1 , 20.	0.3	0
723	Day or night blood pressures for prognosis – Authors' reply. Lancet, The, 2008, 371, 114-115.	6.3	O
724	Segmental Renal Sodium Handling in Relation to the Human SAH Gene. Hypertension, 2008, 52, e12-3.	1.3	0
725	Can lowering blood pressure prevent vascular complications in patients with type 2 diabetes?. Nature Clinical Practice Cardiovascular Medicine, 2008, 5, 194-195.	3.3	0
726	Response to Determinants of the Ambulatory Arterial Stiffness Index Regression Line. Hypertension, 2009, 53, .	1.3	0
727	Sex-specific relative and absolute risks associated with the conventional and ambulatory blood pressures in 9357 subjects from 11 populations. International Journal of Cardiology, 2009, 137, S21-S22.	0.8	0
728	Prognostic value of short-term blood pressure variability over 24 h in 8938 subjects from 11 populations. International Journal of Cardiology, 2009, 137, S22.	0.8	0
729	Morbidity and mortality on combination versus monotherapy in the Systolic Hypertension in Europe Trial. International Journal of Cardiology, 2009, 137, S39-S40.	0.8	0
730	Telomere length predicts left ventricular mass in a general population. International Journal of Cardiology, 2009, 137, S82-S83.	0.8	0
731	Comments on the reproducibility of ambulatory arterial stiffness index and QRS Korotkoff delay index. Journal of Hypertension, 2009, 27, 436-437.	0.3	0
732	Conventional and 24-h ambulatory blood pressure as independent predictors of elastic arterial properties. Blood Pressure Monitoring, 2009, 14, 12-19.	0.4	0
733	Response to Indices of Blood Pressure Variability and Cardiovascular Risk. Hypertension, 2010, 56, .	1.3	0
734	Online journals: paying or delaying?. Lancet, The, 2010, 375, 984.	6.3	0
735	Response to Referral of Women to Ambulatory Blood Pressure Monitoring. Hypertension, 2011, 57, .	1.3	0
736	White-coat Hypertension on Automated Blood Pressure Measurement: Implications for Clinical Practice. The European Journal of Cardiovascular Medicine, 2011, , .	1.0	0
737	Urinary Sodium Excretion and Cardiovascular Disease Mortalityâ€"Reply. JAMA - Journal of the American Medical Association, 2011, 306, 1083.	3.8	0
738	Averaging clinic and home measures associated with reductions in within-patient variability and may give a better indication of blood pressure control. Evidence-Based Medicine, 2012, 17, 82-83.	0.6	0

#	Article	IF	CITATIONS
739	Response to Phenotyping the Microcirculation With Contrast-Enhanced Ultrasound. Hypertension, 2012, 60, .	1.3	0
740	Reply. Journal of Hypertension, 2017, 35, 2327-2328.	0.3	0
741	Antihypertensive treatment decreases arterial stiffness at night but not during the day. Results from the Hypertension in the Very Elderly Trial. Blood Pressure, 2017, 26, 109-114.	0.7	0
742	Resistant Hypertension. Hypertension, 2018, 71, 772-780.	1.3	0
743	Diastolic left ventricular function in relation to the retinal microvascular fractal dimension in a Flemish population. Hypertension Research, 2021, 44, 446-453.	1.5	O
744	Are the benefits of antihypertensive therapy only due to blood pressure reduction?. Journal of Hypertension, 2002, 20, 2096-2097.	0.3	0
745	"Sexual Maturation in Relation to Polychlorinated Aromatic Hydrocarbons": Den Hond et al.'s Response. Environmental Health Perspectives, 2003, 111, a202-a203.	2.8	0
746	Outcome-Driven Thresholds for Pulse Pressure on Office and Out-of-the-Office Blood Pressure Measurement., 2014,, 447-457.		0
747	Cancer and Cadmium. , 2015, , 741-743.		O
748	Cancer and Cadmium., 2015, , 1-3.		0
749	Home Blood Pressure as Predictor of Adverse Health Outcomes. Updates in Hypertension and Cardiovascular Protection, 2020, , 33-43.	0.1	0
750	Commentary: "Lower is Better―— SPRINTing to STEPping up hypertension research? An historical perspective on hypertension trials. International Journal of Cardiology Cardiovascular Risk and Prevention, 2021, 11, 200122.	0.4	0